BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360. [PMID: 15032581 DOI: 10.1146/annurev.immunol.22.012703.104803] [Cited by in Crossref: 1653] [Cited by in F6Publishing: 1461] [Article Influence: 91.8] [Reference Citation Analysis]
Number Citing Articles
1 Khajanchi S. Modeling the dynamics of glioma-immune surveillance. Chaos, Solitons & Fractals 2018;114:108-18. [DOI: 10.1016/j.chaos.2018.06.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
2 Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91. [PMID: 15753211 DOI: 10.1084/jem.20041684] [Cited by in Crossref: 323] [Cited by in F6Publishing: 291] [Article Influence: 19.0] [Reference Citation Analysis]
3 Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25:387-408. [PMID: 17043764 DOI: 10.1007/s10555-006-9004-4] [Cited by in Crossref: 361] [Cited by in F6Publishing: 356] [Article Influence: 24.1] [Reference Citation Analysis]
4 Stratikos E, Stamogiannos A, Zervoudi E, Fruci D. A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition. Front Oncol 2014;4:363. [PMID: 25566501 DOI: 10.3389/fonc.2014.00363] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
5 Dang Y, Shi X, Xu W, Zuo M. The Effect of Anesthesia on the Immune System in Colorectal Cancer Patients. Can J Gastroenterol Hepatol 2018;2018:7940603. [PMID: 29805965 DOI: 10.1155/2018/7940603] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
6 Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208:1989-2003. [PMID: 21930769 DOI: 10.1084/jem.20101158] [Cited by in Crossref: 585] [Cited by in F6Publishing: 561] [Article Influence: 53.2] [Reference Citation Analysis]
7 Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761-773. [PMID: 28382138 DOI: 10.7150/jca.17648] [Cited by in Crossref: 505] [Cited by in F6Publishing: 492] [Article Influence: 101.0] [Reference Citation Analysis]
8 Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950. [PMID: 25981182 DOI: 10.1111/cas.12695] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
9 Miskad UA, Rifai RA, Masadah R, Nelwan B, Ahmad D, Cangara H, Prihantono P, Zainuddin AA, Rahawarin H. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type. Breast Dis 2021;40:S9-S14. [PMID: 34092582 DOI: 10.3233/BD-219002] [Reference Citation Analysis]
10 Aloysius M, Robins R, Eremin J, Eremin O. Vaccination therapy in malignant disease. The Surgeon 2006;4:309-20. [DOI: 10.1016/s1479-666x(06)80008-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Quaglino E, Riccardo F, Macagno M, Bandini S, Cojoca R, Ercole E, Amici A, Cavallo F. Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers (Basel) 2011;3:3225-41. [PMID: 24212954 DOI: 10.3390/cancers3033225] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fridman WH, Mlecnik B, Bindea G, Pagès F, Galon J. Immunosurveillance in human non-viral cancers. Curr Opin Immunol 2011;23:272-8. [PMID: 21237631 DOI: 10.1016/j.coi.2010.12.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
13 Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines. 2008;7:881-887. [PMID: 18767939 DOI: 10.1586/14760584.7.7.881] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
14 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
15 Tsuchikawa T, Ikeda H, Cho Y, Miyamoto M, Shichinohe T, Hirano S, Kondo S. Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol. 2011;164:50-56. [PMID: 21352198 DOI: 10.1111/j.1365-2249.2010.04311.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
16 Kouketsu A, Sato I, Oikawa M, Shimizu Y, Saito H, Tashiro K, Yamashita Y, Takahashi T, Kumamoto H. Regulatory T cells and M2-polarized tumour-associated macrophages are associated with the oncogenesis and progression of oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2019;48:1279-88. [PMID: 31053518 DOI: 10.1016/j.ijom.2019.04.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
17 Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res 2009;28:329-47. [PMID: 19563908 DOI: 10.1016/j.preteyeres.2009.06.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
18 Pham T, Roth S, Kong J, Guerra G, Narasimhan V, Pereira L, Desai J, Heriot A, Ramsay R. An Update on Immunotherapy for Solid Tumors: A Review. Ann Surg Oncol 2018;25:3404-12. [DOI: 10.1245/s10434-018-6658-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
19 Arens R. Rational Design of Vaccines. Synthetic Vaccines. Elsevier; 2012. pp. 217-43. [DOI: 10.1016/b978-0-12-396548-6.00009-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
20 Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, Wang B, Wang Q, Zhao Y, Cai Y. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol 2020;88:106939. [PMID: 33182039 DOI: 10.1016/j.intimp.2020.106939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
21 Newnes HV, Armitage JD, Audsley KM, Bosco A, Waithman J. Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. Cancers (Basel) 2021;13:5911. [PMID: 34885021 DOI: 10.3390/cancers13235911] [Reference Citation Analysis]
22 Forlani G, Shallak M, Celesti F, Accolla RS. Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. Cancers (Basel) 2020;12:E3181. [PMID: 33138029 DOI: 10.3390/cancers12113181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS 2018;126:732-8. [PMID: 30160018 DOI: 10.1111/apm.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
24 Smyth MJ. Type I interferon and cancer immunoediting. Nat Immunol 2005;6:646-8. [DOI: 10.1038/ni0705-646] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
25 Szalontai K, Gémes N, Furák J, Varga T, Neuperger P, Balog JÁ, Puskás LG, Szebeni GJ. Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer. J Clin Med 2021;10:2889. [PMID: 34209651 DOI: 10.3390/jcm10132889] [Reference Citation Analysis]
26 Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, Chu Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol 2011;186:1963-9. [PMID: 21217015 DOI: 10.4049/jimmunol.1002320] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
27 Pérez-Romero K, Rodríguez RM, Amedei A, Barceló-Coblijn G, Lopez DH. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. Int J Mol Sci 2020;21:E5521. [PMID: 32752264 DOI: 10.3390/ijms21155521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tang M, Gao X, Sun H, Tian S, Dong J, Liu Z, Liu W. Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis. J Oncol 2021;2021:6688346. [PMID: 33542732 DOI: 10.1155/2021/6688346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yutong H, Xiaoli X, Shumei L, Shan S, Di L, Baoen S. Increased Neutrophil-Lymphocyte Ratio Is a Poor Prognostic Factor in Patients with Esophageal Cancer in a High Incidence Area in China. Arch Med Res 2015;46:557-63. [PMID: 26385485 DOI: 10.1016/j.arcmed.2015.09.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
30 Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett 2017;17:1326-35. [PMID: 28273716 DOI: 10.1021/acs.nanolett.6b03329] [Cited by in Crossref: 236] [Cited by in F6Publishing: 222] [Article Influence: 39.3] [Reference Citation Analysis]
31 Erreni M, Mantovani A, Allavena P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron. 2011;4:141-154. [PMID: 21909876 DOI: 10.1007/s12307-010-0052-5] [Cited by in Crossref: 205] [Cited by in F6Publishing: 204] [Article Influence: 17.1] [Reference Citation Analysis]
32 Grange J, Brunet LR, Rieder H. Immune protection against tuberculosis – When is immunotherapy preferable to vaccination? Tuberculosis 2011;91:179-85. [DOI: 10.1016/j.tube.2010.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
33 Fernando RC, de Carvalho F, Mazzotti DR, Evangelista AF, Braga WMT, de Lourdes Chauffaille M, Leme AFP, Colleoni GWB. Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets. Genes Cancer 2015;6:462-71. [PMID: 26807199 DOI: 10.18632/genesandcancer.88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
34 Manjili MH. Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. Cancer Res 2017;77:2564-9. [PMID: 28507050 DOI: 10.1158/0008-5472.CAN-17-0068] [Cited by in Crossref: 54] [Cited by in F6Publishing: 30] [Article Influence: 10.8] [Reference Citation Analysis]
35 Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-worms DR, Ley TJ. Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance. Immunity 2007;27:635-46. [DOI: 10.1016/j.immuni.2007.08.014] [Cited by in Crossref: 453] [Cited by in F6Publishing: 442] [Article Influence: 30.2] [Reference Citation Analysis]
36 Ingold Heppner B, Loibl S, Denkert C. Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care (Basel) 2016;11:96-100. [PMID: 27239170 DOI: 10.1159/000444357] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
37 Donadon M, Lleo A, Di Tommaso L, Soldani C, Franceschini B, Roncalli M, Torzilli G. The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Front Oncol 2018;8:181. [PMID: 29892573 DOI: 10.3389/fonc.2018.00181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
38 Wang Y, Wang X, Zhao R. The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population. Int J Immunogenet 2015;42:93-9. [PMID: 25689638 DOI: 10.1111/iji.12181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
39 Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P. A tumor specific antibody to aid breast cancer screening in women with dense breast tissue. Genes Cancer 2017;8:536-49. [PMID: 28680538 DOI: 10.18632/genesandcancer.134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
40 Papaioannou E, González-Molina MDP, Prieto-Muñoz AM, Gámez-Reche L, González-Martín A. Regulation of Adaptive Tumor Immunity by Non-Coding RNAs. Cancers (Basel) 2021;13:5651. [PMID: 34830805 DOI: 10.3390/cancers13225651] [Reference Citation Analysis]
41 Garrido F. Introduction. Adv Exp Med Biol 2019;1151:1-14. [PMID: 31140105 DOI: 10.1007/978-3-030-17864-2_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Zhang DM, Bao YL, Yu CL, Wang YM, Song ZB. Cripto-1 modulates macrophage cytokine secretion and phagocytic activity via NF-κB signaling. Immunol Res 2016;64:104-14. [PMID: 26476731 DOI: 10.1007/s12026-015-8724-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
43 Kvízová J, Pavlíčková V, Kmoníčková E, Ruml T, Rimpelová S. Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions. Molecules 2021;26:2228. [PMID: 33921501 DOI: 10.3390/molecules26082228] [Reference Citation Analysis]
44 Donadon M, Cortese N, Marchesi F, Cimino M, Mantovani A, Torzilli G. Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients. Hepatobiliary Surg Nutr 2019;8:370-7. [PMID: 31489306 DOI: 10.21037/hbsn.2019.03.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Shabaneh TB, Molodtsov AK, Steinberg SM, Zhang P, Torres GM, Mohamed GA, Boni A, Curiel TJ, Angeles CV, Turk MJ. Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. Cancer Res 2018;78:5038-49. [PMID: 30026331 DOI: 10.1158/0008-5472.CAN-18-0365] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
46 Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2011;11:997-1009. [PMID: 21675925 DOI: 10.1517/14712598.2011.575357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
47 Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610-618. [PMID: 21245428 DOI: 10.1200/jco.2010.30.5425] [Cited by in Crossref: 610] [Cited by in F6Publishing: 381] [Article Influence: 55.5] [Reference Citation Analysis]
48 Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. J Immunother Cancer. 2019;7:309. [PMID: 31735170 DOI: 10.1186/s40425-019-0769-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
49 Blanchard L, Girard JP. High endothelial venules (HEVs) in immunity, inflammation and cancer. Angiogenesis 2021. [PMID: 33956259 DOI: 10.1007/s10456-021-09792-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
50 Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE. TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother 2012;61:1627-38. [PMID: 22350070 DOI: 10.1007/s00262-012-1217-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
51 Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A 2014;111:5998-6003. [PMID: 24711415 DOI: 10.1073/pnas.1209067111] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
52 Koumantou D, Barnea E, Martin-Esteban A, Maben Z, Papakyriakou A, Mpakali A, Kokkala P, Pratsinis H, Georgiadis D, Stern LJ, Admon A, Stratikos E. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1). Cancer Immunol Immunother 2019;68:1245-61. [PMID: 31222486 DOI: 10.1007/s00262-019-02358-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
53 Sadeghian M, Rahmani S, Khalesi S, Hejazi E. A review of fasting effects on the response of cancer to chemotherapy. Clin Nutr 2021;40:1669-81. [PMID: 33153820 DOI: 10.1016/j.clnu.2020.10.037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Berzofsky JA. Improving immunotherapy: revisiting the immunologist's little secret. Sci Transl Med 2012;4:120fs4. [PMID: 22323826 DOI: 10.1126/scitranslmed.3003658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Roulois D, Grégoire M, Fonteneau JF. MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int 2013;2013:871936. [PMID: 23509794 DOI: 10.1155/2013/871936] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
56 Krupp M, Maass T, Marquardt JU, Staib F, Bauer T, König R, Biesterfeld S, Galle PR, Tresch A, Teufel A. The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. BMC Med Genomics 2011;4:53. [PMID: 21718500 DOI: 10.1186/1755-8794-4-53] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
57 Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, Jiang T, Wu A. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 2014;110:2560-8. [PMID: 24691423 DOI: 10.1038/bjc.2014.162] [Cited by in Crossref: 157] [Cited by in F6Publishing: 160] [Article Influence: 19.6] [Reference Citation Analysis]
58 Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics 2009;10:240-9. [PMID: 19949545 DOI: 10.2174/138920209788488553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
59 Burkart C, Arimoto K, Tang T, Cong X, Xiao N, Liu YC, Kotenko SV, Ellies LG, Zhang DE. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med 2013;5:1035-50. [PMID: 23681607 DOI: 10.1002/emmm.201201864] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
60 Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer 2018;18:1-19. [PMID: 29629216 DOI: 10.5230/jgc.2018.18.e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
61 Robert J. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. Dev Comp Immunol 2010;34:915-25. [PMID: 20553753 DOI: 10.1016/j.dci.2010.05.011] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
62 Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P. Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 2016;120:1-12. [PMID: 27345592 DOI: 10.1016/j.radonc.2016.06.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
63 Schmidt K, Wies E, Neipel F. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. J Virol 2011;85:4530-7. [PMID: 21345951 DOI: 10.1128/JVI.02123-10] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
64 Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008;57:907-12. [PMID: 18004566 DOI: 10.1007/s00262-007-0414-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
65 Shi R, Tang Y, Miao H. Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm 2020;1:47-68. [DOI: 10.1002/mco2.6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
66 Gong Y, Fan Z, Luo G, Huang Q, Qian Y, Cheng H, Jin K, Ni Q, Yu X, Liu C. Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients. Cancer Manag Res 2020;12:6727-37. [PMID: 32848455 DOI: 10.2147/CMAR.S257492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Zhao L, Li W, Wang Z, Yang Y, Zhang Y, Shang Y, Ren X, Gao Q. Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma. Immunotherapy 2018;10:501-10. [PMID: 29562855 DOI: 10.2217/imt-2017-0140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
68 Nasti TH, Iqbal O, Tamimi IA, Geise JT, Katiyar SK, Yusuf N. Differential roles of T-cell subsets in regulation of ultraviolet radiation induced cutaneous photocarcinogenesis. Photochem Photobiol 2011;87:387-98. [PMID: 21143237 DOI: 10.1111/j.1751-1097.2010.00859.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
69 Akins EJ, Dubey P. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med 2008;49 Suppl 2:180S-95S. [PMID: 18523073 DOI: 10.2967/jnumed.107.045971] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
70 Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR. Cancer immunoediting and "spontaneous" tumor regression. Pathol Res Pract 2010;206:1-8. [PMID: 19945228 DOI: 10.1016/j.prp.2009.10.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
71 Patra MC, Shah M, Choi S. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Semin Cancer Biol 2020;64:61-82. [PMID: 31054927 DOI: 10.1016/j.semcancer.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
72 Grizzi F, Bianchi P, Malesci A, Laghi L. Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol 2013; 19(2): 174-184 [PMID: 23345940 DOI: 10.3748/wjg.v19.i2.174] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
73 Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow KL, Wilson GD, Miller CR, Chinnaiyan P. Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma. Clin Cancer Res 2018;24:3632-43. [PMID: 29691296 DOI: 10.1158/1078-0432.CCR-18-0041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
74 Bullock TNJ. Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines. Clin Transl Sci 2021;14:120-31. [PMID: 32770735 DOI: 10.1111/cts.12856] [Reference Citation Analysis]
75 Gong N, Zhang Y, Zhang Z, Li X, Liang X. Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Adv Funct Mater 2019;29:1806087. [DOI: 10.1002/adfm.201806087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
76 Atakan S, Bayiz H, Sak S, Poyraz A, Vural B, Yildirim AS, Demirag F, Gure AO. Autologous anti-SOX2 antibody responses reflect intensity but not frequency of antigen expression in small cell lung cancer. BMC Clin Pathol 2014;14:24. [PMID: 24940116 DOI: 10.1186/1472-6890-14-24] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
77 Peppas I, Sollie S, Josephs DH, Hammar N, Walldius G, Karagiannis SN, Van Hemelrijck M. Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Cancer Epidemiology 2019;62:101584. [DOI: 10.1016/j.canep.2019.101584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Berzofsky JA, Wood LV, Terabe M. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. Expert Rev Vaccines 2013;12:1115-8. [PMID: 24124874 DOI: 10.1586/14760584.2013.836906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
79 Morrot A, da Fonseca LM, Salustiano EJ, Gentile LB, Conde L, Filardy AA, Franklim TN, da Costa KM, Freire-de-Lima CG, Freire-de-Lima L. Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. Front Oncol 2018;8:81. [PMID: 29629338 DOI: 10.3389/fonc.2018.00081] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
80 Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 2020;20:12-25. [PMID: 31806885 DOI: 10.1038/s41568-019-0224-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 30.0] [Reference Citation Analysis]
81 Chen H, Ge XL, Zhang ZY, Liu M, Wu RY, Zhang XF, Xu LP, Cheng HY, Sun XC, Zhu HC. M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma. Transl Lung Cancer Res 2021;10:2172-92. [PMID: 34164268 DOI: 10.21037/tlcr-21-351] [Reference Citation Analysis]
82 Hames-fathi S, Nottley SWG, Pillay N. Unravelling undifferentiated soft tissue sarcomas: insights from genomics. Histopathology 2022;80:109-21. [DOI: 10.1111/his.14446] [Reference Citation Analysis]
83 Wang L, Pegram MD, Wu JC. Induced pluripotent stem cells as a novel cancer vaccine. Expert Opin Biol Ther 2019;19:1191-7. [PMID: 31364894 DOI: 10.1080/14712598.2019.1650909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
84 Chong ZX, Yeap SK, Ho WY. Roles of circulating microRNA(s) in human breast cancer. Archives of Biochemistry and Biophysics 2020;695:108583. [DOI: 10.1016/j.abb.2020.108583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Guillerey C, Smyth MJ. NK Cells and Cancer Immunoediting.Curr Top Microbiol Immunol. 2016;395:115-145. [PMID: 26025472 DOI: 10.1007/82_2015_446] [Cited by in Crossref: 25] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
86 Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27-41. [PMID: 31315034 DOI: 10.1016/j.immuni.2019.06.025] [Cited by in Crossref: 335] [Cited by in F6Publishing: 347] [Article Influence: 111.7] [Reference Citation Analysis]
87 Kang BW, Kim JG, Lee IH, Bae HI, Seo AN. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. World J Gastrointest Oncol 2017; 9(7): 293-299 [PMID: 28808502 DOI: 10.4251/wjgo.v9.i7.293] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
88 Deguine J, Breart B, Lemaître F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity 2010;33:632-44. [PMID: 20951068 DOI: 10.1016/j.immuni.2010.09.016] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 7.8] [Reference Citation Analysis]
89 An N, Wang H, Jia W, Jing W, Liu C, Zhu H, Yu J. The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer. J Transl Med 2019;17:402. [PMID: 31796037 DOI: 10.1186/s12967-019-02160-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
90 Al-Tameemi M, Chaplain M, d'Onofrio A. Evasion of tumours from the control of the immune system: consequences of brief encounters. Biol Direct 2012;7:31. [PMID: 23009638 DOI: 10.1186/1745-6150-7-31] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
91 Matsushita T, Takada W, Igarashi K, Naruchi K, Miyoshi R, Garcia-Martin F, Amano M, Hinou H, Nishimura S. A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides. Biochim Biophys Acta 2014;1840:1105-16. [PMID: 24246952 DOI: 10.1016/j.bbagen.2013.11.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
92 Hu X, Wu T, Bao Y, Zhang Z. Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. J Control Release 2017;256:26-45. [PMID: 28434891 DOI: 10.1016/j.jconrel.2017.04.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
93 Liu K. Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer. World J Gastrointest Oncol 2010; 2(11): 399-406 [PMID: 21160903 DOI: 10.4251/wjgo.v2.i11.399] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
94 Kherreh N, Cleary S, Seoighe C. No evidence that HLA genotype influences the driver mutations that occur in cancer patients. Cancer Immunol Immunother 2021. [PMID: 34417841 DOI: 10.1007/s00262-021-03028-w] [Reference Citation Analysis]
95 Hindley JP, Ferreira C, Jones E, Lauder SN, Ladell K, Wynn KK, Betts GJ, Singh Y, Price DA, Godkin AJ, Dyson J, Gallimore A. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011;71:736-46. [PMID: 21156649 DOI: 10.1158/0008-5472.CAN-10-1797] [Cited by in Crossref: 86] [Cited by in F6Publishing: 56] [Article Influence: 7.2] [Reference Citation Analysis]
96 Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007;67:1832-41. [PMID: 17308126 DOI: 10.1158/0008-5472.CAN-06-3014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
97 Deepak P, Acharya A. Anti-tumor immunity and mechanism of immunosuppression mediated by tumor cells: role of tumor-derived soluble factors and cytokines. Int Rev Immunol 2010;29:421-58. [PMID: 20635882 DOI: 10.3109/08830185.2010.483027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
98 Park YH. The nuclear factor-kappa B pathway and response to treatment in breast cancer. Pharmacogenomics 2017;18:1697-709. [PMID: 29182047 DOI: 10.2217/pgs-2017-0044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
99 Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1-14. [PMID: 17386080 DOI: 10.1111/j.1365-2567.2007.02587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Seliger B. Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 2008;5:361-7. [PMID: 19404870 DOI: 10.1080/15476910802482870] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
101 Di J, Zhuang M, Yang H, Jiang B, Wang Z, Su X. Clinical significance of circulating immune cells in left- and right-sided colon cancer. PeerJ 2017;5:e4153. [PMID: 29230377 DOI: 10.7717/peerj.4153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
102 Russ AJ, Xu K, Wentworth L, Alam S, Meyers JV, Macklin MD, Rakhmilevich AL, Rajamanickam V, Suresh M, Cho CS. Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion. Cell Immunol 2011;271:104-9. [PMID: 21741629 DOI: 10.1016/j.cellimm.2011.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
103 Li C. Identifying the optimal anticancer targets from the landscape of a cancer-immunity interaction network. Phys Chem Chem Phys 2017;19:7642-51. [PMID: 28256642 DOI: 10.1039/c6cp07767f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
104 Fridman WH, Sautès-Fridman C. [The tumoral microenvironment: feeding resources, battle field and therapeutic target in cancer]. Med Sci (Paris) 2014;30:359-65. [PMID: 24801028 DOI: 10.1051/medsci/20143004007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
105 von Locquenghien M, Rozalén C, Celià-Terrassa T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest 2021;131:143296. [PMID: 33393507 DOI: 10.1172/JCI143296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Scognamiglio G, Capone M, Mallardo D, Botti G, Ascierto PA, Madonna G. Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. Methods Enzymol 2020;635:21-31. [PMID: 32122547 DOI: 10.1016/bs.mie.2019.07.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Qian H. Cellular Biology in Terms of Stochastic Nonlinear Biochemical Dynamics: Emergent Properties, Isogenetic Variations and Chemical System Inheritability. J Stat Phys 2010;141:990-1013. [DOI: 10.1007/s10955-010-0093-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
108 Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7. [PMID: 20146807 DOI: 10.1186/1756-8722-3-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
109 Basa RC, Davies V, Li X, Murali B, Shah J, Yang B, Li S, Khan MW, Tian M, Tejada R, Hassan A, Washington A Jr, Mukherjee B, Carethers JM, McGuire KL. Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans. PLoS One 2016;11:e0156660. [PMID: 27310868 DOI: 10.1371/journal.pone.0156660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
110 Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010;21:3-10. [PMID: 20005150 DOI: 10.1016/j.cytogfr.2009.11.002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 136] [Article Influence: 10.8] [Reference Citation Analysis]
111 Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. [PMID: 27207108 DOI: 10.1093/annonc/mdw217] [Cited by in Crossref: 219] [Cited by in F6Publishing: 211] [Article Influence: 36.5] [Reference Citation Analysis]
112 Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115-123. [PMID: 16376102 DOI: 10.1016/j.semcancer.2005.11.005] [Cited by in Crossref: 166] [Cited by in F6Publishing: 156] [Article Influence: 10.4] [Reference Citation Analysis]
113 Chen K, Zhang C, Ling S, Wei R, Wang J, Xu X. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis 2021;12:835. [PMID: 34482364 DOI: 10.1038/s41419-021-04116-6] [Reference Citation Analysis]
114 Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20:65-71. [PMID: 20036794 DOI: 10.1016/j.gde.2009.11.004] [Cited by in Crossref: 280] [Cited by in F6Publishing: 305] [Article Influence: 21.5] [Reference Citation Analysis]
115 Liu WN, Fong SY, Tan WWS, Tan SY, Liu M, Cheng JY, Lim S, Suteja L, Huang EK, Chan JKY, Iyer NG, Yeong JPS, Lim DW, Chen Q. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. Cancers (Basel) 2020;12:E1025. [PMID: 32331230 DOI: 10.3390/cancers12041025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
116 Frank MO, Kaufman J, Tian S, Suárez-Fariñas M, Parveen S, Blachère NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB. Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One 2010;5:e12367. [PMID: 20824184 DOI: 10.1371/journal.pone.0012367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
117 Wang F, Multhoff G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021;11:582. [PMID: 33921049 DOI: 10.3390/biom11040582] [Reference Citation Analysis]
118 Iguchi-Manaka A, Okumura G, Ichioka E, Kiyomatsu H, Ikeda T, Bando H, Shibuya A, Shibuya K. High expression of soluble CD155 in estrogen receptor-negative breast cancer. Breast Cancer 2020;27:92-9. [PMID: 31372841 DOI: 10.1007/s12282-019-00999-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
119 Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res. 2013;62:823-834. [PMID: 23868500 DOI: 10.1007/s00011-013-0645-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 9.6] [Reference Citation Analysis]
120 Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Hunborg P, Varvares MA, Hoft DF, Hsueh EC, Peng G. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget. 2015;6:17462-17478. [PMID: 25968569 DOI: 10.18632/oncotarget.3958] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 14.8] [Reference Citation Analysis]
121 De Palma M, Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006;1766:159-66. [PMID: 16857321 DOI: 10.1016/j.bbcan.2006.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 42] [Article Influence: 0.3] [Reference Citation Analysis]
122 Chatterjee S, Das S, Chakraborty P, Manna A, Chatterjee M, Choudhuri SK. Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naïve CD4+ T cells. Immunobiology 2013;218:718-24. [DOI: 10.1016/j.imbio.2012.08.271] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
123 Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics. 2013;13:1637-1653. [PMID: 23335344 DOI: 10.1002/pmic.201200373] [Cited by in Crossref: 235] [Cited by in F6Publishing: 225] [Article Influence: 26.1] [Reference Citation Analysis]
124 Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog 2020;59:775-82. [PMID: 32166821 DOI: 10.1002/mc.23179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
125 Li X, Guo F, Liu Y, Chen HJ, Wen F, Zou B, Li D, Qin Q, Liu X, Shen Y, Wang Y. NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett 2015;10:1533-40. [PMID: 26622704 DOI: 10.3892/ol.2015.3471] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
126 Stapelberg M, Zobalova R, Nguyen MN, Walker T, Stantic M, Goodwin J, Pasdar EA, Thai T, Prokopova K, Yan B, Hall S, de Pennington N, Thomas SR, Grant G, Stursa J, Bajzikova M, Meedeniya AC, Truksa J, Ralph SJ, Ansorge O, Dong L, Neuzil J. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radical Biology and Medicine 2014;67:41-50. [DOI: 10.1016/j.freeradbiomed.2013.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
127 Zins K, Abraham D. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing. Methods Mol Biol 2020;2115:289-325. [PMID: 32006408 DOI: 10.1007/978-1-0716-0290-4_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
128 Shirjang S, Alizadeh N, Mansoori B, Mahmoodpoor A, Kafil HS, Hojjat-Farsangi M, Yousefi M. Promising immunotherapy: Highlighting cytokine-induced killer cells. J Cell Biochem 2019;120:8863-83. [PMID: 30556298 DOI: 10.1002/jcb.28250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
129 Tavakoli F, Sartakhti JS, Manshaei MH, Basanta D. Cancer immunoediting: A game theoretical approach. In Silico Biol 2021;14:1-12. [PMID: 33216021 DOI: 10.3233/ISB-200475] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Wolfson B, Franks SE, Hodge JW. Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines (Basel) 2021;9:509. [PMID: 34063388 DOI: 10.3390/vaccines9050509] [Reference Citation Analysis]
131 Zhao Q, Yu J, Meng X. A good start of immunotherapy in esophageal cancer. Cancer Med. 2019;8:4519-4526. [PMID: 31231980 DOI: 10.1002/cam4.2336] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
132 Eptaminitaki GC, Wolff N, Stellas D, Sifakis K, Baritaki S. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. Cells 2021;10:3313. [PMID: 34943820 DOI: 10.3390/cells10123313] [Reference Citation Analysis]
133 Zhang H, Hou X, Cai H, Zhuang X. Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol 2017;26:207-11. [PMID: 28635405 DOI: 10.1080/13645706.2017.1286356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
134 Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131:1777-1789. [PMID: 29519806 DOI: 10.1182/blood-2017-05-743187] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 22.8] [Reference Citation Analysis]
135 Maire CL, Mohme M, Bockmayr M, Fita KD, Riecken K, Börnigen D, Alawi M, Failla A, Kolbe K, Zapf S, Holz M, Neumann K, Dührsen L, Lange T, Fehse B, Westphal M, Lamszus K. Glioma escape signature and clonal development under immune pressure. J Clin Invest 2020;130:5257-71. [PMID: 32603315 DOI: 10.1172/JCI138760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Khunger A, Sarikonda G, Tsau J, Pahuja A, Alfonso Z, Gao J, Laing C, Vaupel C, Dakappagari N, Tarhini AA. Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma. Transl Oncol 2021;14:101014. [PMID: 33450703 DOI: 10.1016/j.tranon.2021.101014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Vedenko A, Panara K, Goldstein G, Ramasamy R, Arora H. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms. Adv Exp Med Biol 2020;1277:143-58. [PMID: 33119871 DOI: 10.1007/978-3-030-50224-9_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Løset GÅ, Berntzen G, Frigstad T, Pollmann S, Gunnarsen KS, Sandlie I. Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions. Front Oncol 2014;4:378. [PMID: 25629004 DOI: 10.3389/fonc.2014.00378] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Jayakumar H, Seetharaman A, Sunder Singh S, Dhandapani H, Subramani J, Ganeshrajah S, Thangarajan R, Ramanathan P. Combination of IDO1high and CCL19low expression in the tumor tissue reduces survival in HPV positive cervical cancer. J Reprod Immunol 2021;149:103454. [PMID: 34856521 DOI: 10.1016/j.jri.2021.103454] [Reference Citation Analysis]
140 Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 2017;187:53-63. [PMID: 27690272 DOI: 10.1111/cei.12875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
141 Schirrmacher V, Stücker W, Lulei M, Bihari AS, Sprenger T. Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report. Immunotherapy 2015;7:855-60. [PMID: 26020523 DOI: 10.2217/imt.15.48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
142 Rao S, Gharib K, Han A. Cancer Immunosurveillance by T Cells. Int Rev Cell Mol Biol 2019;342:149-73. [PMID: 30635090 DOI: 10.1016/bs.ircmb.2018.08.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
143 Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 2016;375:819-29. [PMID: 27433843 DOI: 10.1056/NEJMoa1604958] [Cited by in Crossref: 1500] [Cited by in F6Publishing: 899] [Article Influence: 250.0] [Reference Citation Analysis]
144 Huang Y, Chen W, Teh BS, Butler EB. Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. J Radiat Oncol 2015;4:365-75. [DOI: 10.1007/s13566-015-0240-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887-904. [PMID: 30361552 DOI: 10.1038/nrd.2018.169] [Cited by in Crossref: 427] [Cited by in F6Publishing: 408] [Article Influence: 106.8] [Reference Citation Analysis]
146 Pandya PH, Murray ME, Pollok KE, Renbarger JL. The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res 2016;2016:4273943. [PMID: 28116316 DOI: 10.1155/2016/4273943] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
147 Tucker ZC, Laguna BA, Moon E, Singhal S. Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev 2012;38:650-61. [PMID: 22226940 DOI: 10.1016/j.ctrv.2011.11.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
148 Wang RF, Peng G, Wang HY. Regulatory T cells and Toll-like receptors in tumor immunity. Semin Immunol. 2006;18:136-142. [PMID: 16469504 DOI: 10.1016/j.smim.2006.01.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
149 Wilkie KP. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy. Adv Exp Med Biol 2013;734:201-34. [PMID: 23143981 DOI: 10.1007/978-1-4614-1445-2_10] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
150 Murray JI, West NR, Murphy LC, Watson PH. Intratumoural inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer. 2015;22:R51-R67. [PMID: 25404688 DOI: 10.1530/erc-14-0096] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
151 Miliotou AN, Papadopoulou LC. In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development. Methods Mol Biol 2020;2086:87-117. [PMID: 31707670 DOI: 10.1007/978-1-0716-0146-4_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
152 Liu X, Venkataraman G, Lin J, Kiyotani K, Smith S, Montoya M, Nakamura Y, Kline J. Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8+ T cells. Oncoimmunology 2015;4:e1002728. [PMID: 26155390 DOI: 10.1080/2162402X.2014.1002728] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
153 Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, Jakobsen BK. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 2012;42:3174-9. [PMID: 22949370 DOI: 10.1002/eji.201242606] [Cited by in Crossref: 151] [Cited by in F6Publishing: 148] [Article Influence: 15.1] [Reference Citation Analysis]
154 Stehle JR Jr, Blanks MJ, Riedlinger G, Kim-Shapiro JW, Sanders AM, Adams JM, Willingham MC, Cui Z. Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR/CR mice. BMC Cancer 2009;9:328. [PMID: 19754973 DOI: 10.1186/1471-2407-9-328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
155 Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77. [PMID: 24332512 DOI: 10.1016/S1470-2045(13)70551-5] [Cited by in Crossref: 382] [Cited by in F6Publishing: 201] [Article Influence: 42.4] [Reference Citation Analysis]
156 Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093-1102. [PMID: 19946335 DOI: 10.1038/onc.2009.416] [Cited by in Crossref: 612] [Cited by in F6Publishing: 568] [Article Influence: 47.1] [Reference Citation Analysis]
157 Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008;319:215-20. [PMID: 18187659 DOI: 10.1126/science.1148886] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
158 Garg NK, Dwivedi P, Prabha P, Tyagi RK. RNA pulsed dendritic cells: An approach for cancer immunotherapy. Vaccine 2013;31:1141-56. [DOI: 10.1016/j.vaccine.2012.12.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
159 Chen S, Liang L, Wang Y, Diao J, Zhao C, Chen G, He Y, Luo C, Wu X, Zhang Y. Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo. Mol Med Rep 2015;12:6727-37. [PMID: 26300071 DOI: 10.3892/mmr.2015.4230] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
160 McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009;15:6993-7002. [PMID: 19861434 DOI: 10.1158/1078-0432.ccr-09-0991] [Cited by in Crossref: 109] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
161 Schirrmacher V, Fournier P, Schlag P. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines. 2014;13:117-130. [PMID: 24219122 DOI: 10.1586/14760584.2014.854169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
162 Himes BT, Geiger PA, Ayasoufi K, Bhargav AG, Brown DA, Parney IF. Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Front Oncol 2021;11:770561. [PMID: 34778089 DOI: 10.3389/fonc.2021.770561] [Reference Citation Analysis]
163 Hurkat P, Jain S, Jain R, Jain A. Immunology Behind Tumors: A Mini Review. CCTR 2019;15:174-83. [DOI: 10.2174/1573394714666180907143433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
164 Shoshan SH, Admon A. Proteomics in cancer vaccine development. Expert Rev Proteomics 2005;2:229-41. [PMID: 15892567 DOI: 10.1586/14789450.2.2.229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
165 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
166 Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. Cancer Lett 2015;368:198-208. [PMID: 25592036 DOI: 10.1016/j.canlet.2015.01.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
167 Ament W, Verkerke GJ. Exercise and Fatigue: . Sports Medicine 2009;39:389-422. [DOI: 10.2165/00007256-200939050-00005] [Cited by in Crossref: 181] [Cited by in F6Publishing: 140] [Article Influence: 13.9] [Reference Citation Analysis]
168 Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, Sweasy JB. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol 2014;49:116-39. [PMID: 24410153 DOI: 10.3109/10409238.2013.875514] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 10.8] [Reference Citation Analysis]
169 Capitini CM, Mackall CL, Wayne AS. Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther 2010;10:163-78. [PMID: 19947897 DOI: 10.1517/14712590903431022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
170 Venteclef N, Ferré P. Liver X receptor: from metabolism to cancer. Biochem J 2014;459:e1-3. [PMID: 24678940 DOI: 10.1042/BJ20140211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
171 Zanetti B, Carvalho-galano D, Feitosa N, Hassumi-fukasawa M, Miranda-camargo F, Maciel L, Ribeiro-silva A, Soares E. Differential Expression of Immune-Modulatory Molecule HLA-E in Non-Neoplastic and Neoplastic Lesions of the Thyroid. Int J Immunopathol Pharmacol 2013;26:889-96. [DOI: 10.1177/039463201302600407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
172 Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M, Mehrabi A. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109:2665-2674. [PMID: 24136146 DOI: 10.1038/bjc.2013.610] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 11.7] [Reference Citation Analysis]
173 Kurbel S, Plestina S, Vrbanec D. Occurrence of the acquired immunity in early vertebrates due to danger of transmissible cancers similar to canine venereal tumors. Medical Hypotheses 2007;68:1185-6. [DOI: 10.1016/j.mehy.2006.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
174 Subramaniam S, Selvaduray KR, Radhakrishnan AK. Bioactive Compounds: Natural Defense Against Cancer? Biomolecules 2019;9:E758. [PMID: 31766399 DOI: 10.3390/biom9120758] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
175 Murugaiyan G, Agrawal R, Mishra GC, Mitra D, Saha B. Differential CD40/CD40L Expression Results in Counteracting Antitumor Immune Responses. J Immunol 2007;178:2047-55. [DOI: 10.4049/jimmunol.178.4.2047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
176 Broos S, Sandin LC, Apel J, Tötterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles. Biomaterials 2012;33:6230-9. [DOI: 10.1016/j.biomaterials.2012.05.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
177 Cao Y, Wang Q, Du Y, Liu F, Zhang Y, Feng Y, Jin F. l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice. Int Immunopharmacol 2016;35:7-14. [PMID: 27003114 DOI: 10.1016/j.intimp.2016.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
178 Kuske M, Rauschenberg R, Garzarolli M, Meredyth-Stewart M, Beissert S, Troost EGC, Glitza OIC, Meier F. Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges. Am J Clin Dermatol 2018;19:529-41. [PMID: 29417399 DOI: 10.1007/s40257-018-0346-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
179 Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA. Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 2018;8:208. [PMID: 29317703 DOI: 10.1038/s41598-017-18540-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
180 Dalessandri T, Crawford G, Hayes M, Castro Seoane R, Strid J. IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. Nat Commun 2016;7:12080. [PMID: 27357235 DOI: 10.1038/ncomms12080] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
181 Lavoué V, Foucher F, Henno S, Bauville E, Catros V, Cabillic F, Levêque J. [Immunotherapy in epithelial ovarian carcinoma: hope and reality]. J Gynecol Obstet Biol Reprod (Paris) 2014;43:198-210. [PMID: 24230482 DOI: 10.1016/j.jgyn.2013.10.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery 2012;71:201-22; discussion 222-3. [PMID: 22353795 DOI: 10.1227/NEU.0b013e31824f840d] [Cited by in Crossref: 57] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
183 Gomes F, Tay R, Chiramel J, Califano R. The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. Drugs Aging 2018;35:819-34. [DOI: 10.1007/s40266-018-0573-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
184 Birtolo C, Go VL, Ptasznik A, Eibl G, Pandol SJ. Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Pancreas 2016;45:21-31. [PMID: 26658038 DOI: 10.1097/MPA.0000000000000531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
185 Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy 2016;8:809-19. [PMID: 27349980 DOI: 10.2217/imt-2016-0001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
186 Purroy N, Wu CJ. Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med 2017;7:a026740. [PMID: 28096240 DOI: 10.1101/cshperspect.a026740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
187 Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SI, Liu K. Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression. Int J Cancer 2008;122:350-62. [PMID: 17918178 DOI: 10.1002/ijc.23090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
188 De Matteis S, Canale M, Verlicchi A, Bronte G, Delmonte A, Crinò L, Martinelli G, Ulivi P. Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. J Oncol 2019;2019:7475364. [PMID: 31531020 DOI: 10.1155/2019/7475364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
189 Galluzzi L, Rudqvist NP. Preface: More than two decades of modern tumor immunology. Methods Enzymol 2020;635:xix-xxxviii. [PMID: 32122557 DOI: 10.1016/S0076-6879(20)30077-X] [Reference Citation Analysis]
190 Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer 2020;8:e000948. [PMID: 33037115 DOI: 10.1136/jitc-2020-000948] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
191 Lynam S, Lugade AA, Odunsi K. Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. Clin Obstet Gynecol 2020;63:48-63. [PMID: 31833846 DOI: 10.1097/GRF.0000000000000513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
192 Pérez-andres M, Almeida J, Martin-ayuso M, Moro MJ, Martin-nuñez G, Galende J, Hernandez J, Mateo G, San Miguel JF, Orfao A. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vβ repertoire: BM T Cells in MG. Cancer 2006;106:1296-305. [DOI: 10.1002/cncr.21746] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
193 Kallen KJ, Theß A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2014;2:10-31. [PMID: 24757523 DOI: 10.1177/2051013613508729] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
194 Hofbauer GF, Bouwes Bavinck JN, Euvrard S. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 2010;19:473-82. [PMID: 20482618 DOI: 10.1111/j.1600-0625.2010.01086.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
195 Wylie B, Chee J, Forbes CA, Booth M, Stone SR, Buzzai A, Abad A, Foley B, Cruickshank MN, Waithman J. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. Oncoimmunology 2019;8:1609874. [PMID: 31413920 DOI: 10.1080/2162402X.2019.1609874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
196 Li Q, Zhang XQ, Nie L, Chen GS, Li H, Zhang F, Zhang LY, Hong L, Wang SF, Wang H. Expression of interferon-gamma in human adrenal gland and kidney tumours. Br J Cancer 2007;97:420-5. [PMID: 17622250 DOI: 10.1038/sj.bjc.6603870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
197 d’Onofrio A. Tumor evasion from immune control: Strategies of a MISS to become a MASS. Chaos, Solitons & Fractals 2007;31:261-8. [DOI: 10.1016/j.chaos.2005.10.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
198 Kowalewski A, Zdrenka M, Grzanka D, Szylberg Ł. Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2020;12:E3300. [PMID: 33182233 DOI: 10.3390/cancers12113300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Shoshan SH, Admon A. MHC-bound antigens and proteomics for novel target discovery. Pharmacogenomics 2004;5:845-59. [DOI: 10.1517/14622416.5.7.845] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
200 Jensen BA, Pedersen SR, Christensen JP, Thomsen AR. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS One 2013;8:e66081. [PMID: 23785471 DOI: 10.1371/journal.pone.0066081] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
201 López ÁG, Seoane JM, Sanjuán MAF. Dynamics of the cell-mediated immune response to tumour growth. Philos Trans A Math Phys Eng Sci 2017;375:20160291. [PMID: 28507236 DOI: 10.1098/rsta.2016.0291] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
202 Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol 2019;10:453. [PMID: 30941125 DOI: 10.3389/fimmu.2019.00453] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 29.3] [Reference Citation Analysis]
203 Dougan M, Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med 2008;205:267-70. [PMID: 18268042 DOI: 10.1084/jem.20080136] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
204 Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res 2009;69:2026-33. [PMID: 19223534 DOI: 10.1158/0008-5472.CAN-08-3706] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
205 Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 2007;26:4106-14. [PMID: 17237823 DOI: 10.1038/sj.onc.1210197] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 3.9] [Reference Citation Analysis]
206 Lamagna C, Aurrand-lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. Journal of Leukocyte Biology 2006;80:705-13. [DOI: 10.1189/jlb.1105656] [Cited by in Crossref: 205] [Cited by in F6Publishing: 194] [Article Influence: 12.8] [Reference Citation Analysis]
207 Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N, Zheng S, Fang Y, Wang J. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. Front Oncol 2021;11:582664. [PMID: 34631507 DOI: 10.3389/fonc.2021.582664] [Reference Citation Analysis]
208 Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A 2010;107:4652-7. [PMID: 20133772 DOI: 10.1073/pnas.0914879107] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
209 Alb M, Sie C, Adam C, Chen S, Becker JC, Schrama D. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. Cancer Immunol Immunother 2012;61:2239-49. [PMID: 22674057 DOI: 10.1007/s00262-012-1290-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
210 Alderson KL, Murphy WJ. Antigen Specific Memory T Cells and Their Putative Need for the Generation of Sustained Anti-Tumor Responses. In: Zanetti M, Schoenberger SP, editors. Memory T Cells. New York: Springer; 2010. pp. 155-65. [DOI: 10.1007/978-1-4419-6451-9_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
211 Naghavi AO, Johnstone PA, Kim S. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Curr Probl Cancer 2016;40:38-67. [PMID: 26656977 DOI: 10.1016/j.currproblcancer.2015.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
212 Llera AS, Girotti MR, Benedetti LG, Podhajcer OL. Matricellular proteins and inflammatory cells: A task force to promote or defeat cancer? Cytokine & Growth Factor Reviews 2010;21:67-76. [DOI: 10.1016/j.cytogfr.2009.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
213 Doss M. Shifting the paradigm in radiation safety. Dose Response. 2012;10:562-583. [PMID: 23304105 DOI: 10.2203/dose-response.11-056.doss] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
214 Green JS, Tsui BCH. Impact of anesthesia for cancer surgery: Continuing Professional Development. Can J Anesth/J Can Anesth 2013;60:1248-69. [DOI: 10.1007/s12630-013-0037-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
215 Russo V. Metabolism, LXR/LXR ligands, and tumor immune escape. Journal of Leukocyte Biology 2011;90:673-9. [DOI: 10.1189/jlb.0411198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
216 Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41-53. [PMID: 23667165 DOI: 10.1189/jlb.1212631] [Cited by in Crossref: 206] [Cited by in F6Publishing: 192] [Article Influence: 22.9] [Reference Citation Analysis]
217 Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E Protects Glioma Cells from NKG2D-Mediated Immune Responses In Vitro: Implications for Immune Escape In Vivo. J Neuropathol Exp Neurol 2005;64:523-8. [DOI: 10.1093/jnen/64.6.523] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 5.9] [Reference Citation Analysis]
218 Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci. 2011;68:369-395. [PMID: 21107637 DOI: 10.1007/s00018-010-0580-7] [Cited by in Crossref: 207] [Cited by in F6Publishing: 195] [Article Influence: 17.3] [Reference Citation Analysis]
219 Zimmermann VS, Benigni F, Mondino A. Immune surveillance and anti-tumor immune responses: an anatomical perspective. Immunology Letters 2005;98:1-8. [DOI: 10.1016/j.imlet.2004.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
220 d’Onofrio A, Ledzewicz U, Schättler H. On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy. In: d’Onofrio A, Cerrai P, Gandolfi A, editors. New Challenges for Cancer Systems Biomedicine. Milano: Springer Milan; 2012. pp. 249-66. [DOI: 10.1007/978-88-470-2571-4_13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
221 Li Q, Liu Q. Noncoding RNAs in Cancer Immunology. Adv Exp Med Biol 2016;927:243-64. [PMID: 27376738 DOI: 10.1007/978-981-10-1498-7_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
222 Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy. Int J Cancer 2010;127:1614-24. [PMID: 20091859 DOI: 10.1002/ijc.25183] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
223 Wu X, Peng M, Huang B, Zhang H, Wang H, Huang B, Xue Z, Zhang L, Da Y, Yang D, Yao Z, Zhang R. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 2013;340:124-33. [PMID: 23920127 DOI: 10.1016/j.canlet.2013.07.038] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
224 Chacon JA, Schutsky K, Powell DJ. The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines (Basel) 2016;4:E43. [PMID: 27854240 DOI: 10.3390/vaccines4040043] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
225 Sekhon BK, Roubin RH, Li Y, Devi PB, Nammi S, Fan K, Sze DM. Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy. PLoS One 2016;11:e0146881. [PMID: 26799072 DOI: 10.1371/journal.pone.0146881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
226 Chen X, Cao Z, Zhang Y, Li J, Wang S, Du J, Liao L. Fuzheng Qingjie Granules Inhibit Growth of Hepatoma Cells via Inducing Mitochondria-Mediated Apoptosis and Enhancing Immune Function. Integr Cancer Ther 2017;16:329-38. [PMID: 27335087 DOI: 10.1177/1534735416654761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
227 DeVita VT Jr, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nat Rev Clin Oncol 2014;11:663-9. [PMID: 25245981 DOI: 10.1038/nrclinonc.2014.153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
228 Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011;108:16723-8. [PMID: 21933959 DOI: 10.1073/pnas.1110814108] [Cited by in Crossref: 247] [Cited by in F6Publishing: 227] [Article Influence: 22.5] [Reference Citation Analysis]
229 Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27:334-348. [PMID: 17656116 DOI: 10.1016/j.immuni.2007.05.020] [Cited by in Crossref: 269] [Cited by in F6Publishing: 247] [Article Influence: 17.9] [Reference Citation Analysis]
230 Mocellin S, Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med Res Rev 2008;28:413-44. [PMID: 17694549 DOI: 10.1002/med.20110] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
231 Drake CG. Combination immunotherapy approaches. Ann Oncol. 2012;23 Suppl 8:viii41-viii46. [PMID: 22918927 DOI: 10.1093/annonc/mds262] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 9.2] [Reference Citation Analysis]
232 George J, Banik NL, Ray SK. Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin Cancer Res 2009;15:7186-95. [PMID: 19934306 DOI: 10.1158/1078-0432.CCR-09-1425] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
233 Wirth TC, Kühnel F. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy? Front Immunol 2017;8:1848. [PMID: 29312332 DOI: 10.3389/fimmu.2017.01848] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
234 Camus M, Galon J. Memory T-Cell Responses and Survival in Human Cancer: Remember to Stay Alive. In: Zanetti M, Schoenberger SP, editors. Memory T Cells. New York: Springer; 2010. pp. 166-77. [DOI: 10.1007/978-1-4419-6451-9_13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
235 Bevelacqua JJ, Welsh J, Mortazavi SAR, Keshavarz M, Mortazavi SMJ. Space Medicine: Why Do Recently Published Papers about Telomere Length Alterations Increase our Uncertainty Rather than Reduce it? J Biomed Phys Eng 2021;11:103-8. [PMID: 33564645 DOI: 10.31661/jbpe.v0i0.2005-1115] [Reference Citation Analysis]
236 Sistigu A, Musella M, Galassi C, Vitale I, De Maria R. Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. Front Immunol 2020;11:2166. [PMID: 33193295 DOI: 10.3389/fimmu.2020.02166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
237 Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112:1269-1279. [PMID: 18524989 DOI: 10.1182/blood-2008-03-147033] [Cited by in Crossref: 199] [Cited by in F6Publishing: 181] [Article Influence: 14.2] [Reference Citation Analysis]
238 Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, de Kruijf M, Soden D, Tangney M, Collins JK, O’Sullivan GC. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev. 2011;37:618-632. [PMID: 21232872 DOI: 10.1016/j.ctrv.2010.12.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
239 Ivanova AV, Ivanov SV, Pascal V, Lumsden JM, Ward JM, Morris N, Tessarolo L, Anderson SK, Lerman MI. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J Pathol 2007;211:591-601. [PMID: 17318811 DOI: 10.1002/path.2146] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
240 Alexander PG, McMillan DC, Park JH. The local inflammatory response in colorectal cancer - Type, location or density? A systematic review and meta-analysis. Cancer Treat Rev 2020;83:101949. [PMID: 31869737 DOI: 10.1016/j.ctrv.2019.101949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
241 Santana CH, Moreira PRR, Rosolem MC, Vasconcelos RO. Relationship between the inflammatory infiltrate and the degree of differentiation of the canine cutaneous squamous cell carcinoma. Vet Anim Sci 2016;1-2:4-8. [PMID: 32734017 DOI: 10.1016/j.vas.2016.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
242 Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009;69:5514-21. [PMID: 19549903 DOI: 10.1158/0008-5472.CAN-08-4625] [Cited by in Crossref: 120] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
243 Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 2016;5:e1234570. [PMID: 27999749 DOI: 10.1080/2162402X.2016.1234570] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
244 Nocentini G, Cari L, Ronchetti S, Riccardi C. Modulation of tumor immunity: a patent evaluation of WO2015026684A1. Expert Opinion on Therapeutic Patents 2016;26:417-25. [DOI: 10.1517/13543776.2016.1118061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
245 Wrona A. Role of immunotherapy in stage III nonsmall cell lung cancer. Curr Opin Oncol 2019;31:18-23. [PMID: 30489337 DOI: 10.1097/CCO.0000000000000493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
246 Oates J, Jakobsen BK. ImmTACs: Novel bi-specific agents for targeted cancer therapy. Oncoimmunology 2013;2:e22891. [PMID: 23525668 DOI: 10.4161/onci.22891] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
247 Khan AA, Liu ZK, Xu X. Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00124-7. [PMID: 34344612 DOI: 10.1016/j.hbpd.2021.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Wiecek AJ, Jacobson DH, Lason W, Secrier M. Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes. Front Cell Dev Biol 2021;9:698659. [PMID: 34307377 DOI: 10.3389/fcell.2021.698659] [Reference Citation Analysis]
249 Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7:880-887. [PMID: 17957190 DOI: 10.1038/nrc2250] [Cited by in Crossref: 266] [Cited by in F6Publishing: 244] [Article Influence: 17.7] [Reference Citation Analysis]
250 Jin J, Zhao Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics 2020;10:6231-44. [PMID: 32483450 DOI: 10.7150/thno.45219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
251 Wentworth L, Meyers JV, Alam S, Russ AJ, Suresh M, Cho CS. Memory T cells are uniquely resistant to melanoma-induced suppression. Cancer Immunol Immunother 2013;62:149-59. [PMID: 22865267 DOI: 10.1007/s00262-012-1326-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
252 Ioannidou K, Baumgaertner P, Gannon PO, Speiser MF, Allard M, Hebeisen M, Rufer N, Speiser DE. Heterogeneity assessment of functional T cell avidity. Sci Rep 2017;7:44320. [PMID: 28287160 DOI: 10.1038/srep44320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
253 Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, Lu X. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. J Immunother 2016;39:171-80. [PMID: 27070448 DOI: 10.1097/CJI.0000000000000122] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
254 Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011;35:569-74. [PMID: 21143201 DOI: 10.1042/CBI20100431] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
255 Lee SL, Al-Shamkhani A, Mirnezami A. Immuno-oncology for surgeons. Br J Surg 2019;106:1273-82. [PMID: 31318438 DOI: 10.1002/bjs.11224] [Reference Citation Analysis]
256 Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics 2017;9:59. [PMID: 28572863 DOI: 10.1186/s13148-017-0358-y] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 16.4] [Reference Citation Analysis]
257 Murphy MA, O'Leary JJ, Cahill DJ. Assessment of the humoral immune response to cancer. J Proteomics 2012;75:4573-9. [PMID: 22300580 DOI: 10.1016/j.jprot.2012.01.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
258 Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836-848. [PMID: 17063185 DOI: 10.1038/nri1961] [Cited by in Crossref: 973] [Cited by in F6Publishing: 905] [Article Influence: 60.8] [Reference Citation Analysis]
259 McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest 2006;116:2543-51. [PMID: 16932807 DOI: 10.1172/JCI26936] [Cited by in Crossref: 35] [Cited by in F6Publishing: 60] [Article Influence: 2.2] [Reference Citation Analysis]
260 Rubin B, Gairin JE. Concepts and ways to amplify the antitumor immune response. Curr Top Microbiol Immunol 2011;344:97-128. [PMID: 20680804 DOI: 10.1007/82_2010_89] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
261 Goodman MG. Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine. J Immunol. 1986;136:3335-3340. [PMID: 3514757 DOI: 10.1111/j.1476-5381.2012.02099.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 2.4] [Reference Citation Analysis]
262 Marusyk A, Janiszewska M, Polyak K. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell 2020;37:471-84. [PMID: 32289271 DOI: 10.1016/j.ccell.2020.03.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 41.5] [Reference Citation Analysis]
263 Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. Int Immunol 2009;21:655-65. [PMID: 19395374 DOI: 10.1093/intimm/dxp034] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
264 Marrocco I, Romaniello D, Yarden Y. Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods Mol Biol 2019;1904:11-51. [PMID: 30539465 DOI: 10.1007/978-1-4939-8958-4_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
265 Albertus DL, Seder CW, Chen G, Wang X, Hartojo W, Lin L, Silvers A, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Bigbee WL, Chinnaiyan AM, Beer DG. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol. 2008;3:1236-1244. [PMID: 18978557 DOI: 10.1097/jto.0b013e318189f5ec] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
266 Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010;115:3058-69. [PMID: 20008791 DOI: 10.1182/blood-2009-06-227934] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 5.8] [Reference Citation Analysis]
267 Florke Gee RR, Chen H, Lee AK, Daly CA, Wilander BA, Fon Tacer K, Potts PR. Emerging roles of the MAGE protein family in stress response pathways. J Biol Chem 2020;295:16121-55. [PMID: 32921631 DOI: 10.1074/jbc.REV120.008029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
268 Niccolai E, Ricci F, Russo E, Nannini G, Emmi G, Taddei A, Ringressi MN, Melli F, Miloeva M, Cianchi F, Bechi P, Prisco D, Amedei A. The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer. Front Immunol. 2017;8:1900. [PMID: 29375559 DOI: 10.3389/fimmu.2017.01900] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
269 Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M. Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. J Oncol 2019;2019:1856594. [PMID: 31428149 DOI: 10.1155/2019/1856594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
270 Goč S, Janković M. Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia. Dis Markers 2013;35:847-55. [PMID: 24367138 DOI: 10.1155/2013/923819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
271 Deb J, Majumder J, Bhattacharyya S, Jana SS. A novel naproxen derivative capable of displaying anti-cancer and anti-migratory properties against human breast cancer cells. BMC Cancer 2014;14:567. [PMID: 25098498 DOI: 10.1186/1471-2407-14-567] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
272 Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010;40:3347-57. [PMID: 21110318 DOI: 10.1002/eji.201041037] [Cited by in Crossref: 178] [Cited by in F6Publishing: 170] [Article Influence: 16.2] [Reference Citation Analysis]
273 Byers AM, Hadley A, Lukacher AE. Protection against polyoma virus-induced tumors is perforin-independent. Virology 2007;358:485-92. [PMID: 17011010 DOI: 10.1016/j.virol.2006.08.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
274 D'onofrio A. TUMOR-IMMUNE SYSTEM INTERACTION: MODELING THE TUMOR-STIMULATED PROLIFERATION OF EFFECTORS AND IMMUNOTHERAPY. Math Models Methods Appl Sci 2011;16:1375-401. [DOI: 10.1142/s0218202506001571] [Cited by in Crossref: 53] [Article Influence: 4.8] [Reference Citation Analysis]
275 Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 2018;24:1459-68. [PMID: 30104766 DOI: 10.1038/s41591-018-0135-2] [Cited by in Crossref: 191] [Cited by in F6Publishing: 177] [Article Influence: 47.8] [Reference Citation Analysis]
276 Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med 2014;7:357-65. [PMID: 25484597 DOI: 10.2147/PGPM.S53163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 1.1] [Reference Citation Analysis]
277 Yang T, Han Q, Zeng C, Wang H, Fu Y, Zhang C. Delay-induced state transition and resonance in periodically driven tumor model with immune surveillance. Open Physics 2014;12. [DOI: 10.2478/s11534-014-0460-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
278 Ku GY. The Current Status of Immunotherapies in Esophagogastric Cancer. Surg Oncol Clin N Am 2017;26:277-92. [PMID: 28279469 DOI: 10.1016/j.soc.2016.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
279 d’Onofrio A. Metamodeling tumor–immune system interaction, tumor evasion and immunotherapy. Mathematical and Computer Modelling 2008;47:614-37. [DOI: 10.1016/j.mcm.2007.02.032] [Cited by in Crossref: 61] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
280 Raniszewska A, Polubiec-Kownacka M, Rutkowska E, Domagala-Kulawik J. PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates. Stem Cell Rev Rep 2019;15:324-30. [PMID: 30397852 DOI: 10.1007/s12015-018-9860-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
281 Curran EK, Godfrey J, Kline J. Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends Immunol 2017;38:513-25. [PMID: 28511816 DOI: 10.1016/j.it.2017.04.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
282 Levy A, Chargari C, Cheminant M, Simon N, Bourgier C, Deutsch E. Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol Hematol 2013;85:278-87. [PMID: 23036459 DOI: 10.1016/j.critrevonc.2012.09.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
283 Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK, Cui Y. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Front Cell Dev Biol 2019;7:52. [PMID: 31024913 DOI: 10.3389/fcell.2019.00052] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 24.3] [Reference Citation Analysis]
284 Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol 2019;16:613-30. [PMID: 31501534 DOI: 10.1038/s41585-019-0226-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
285 Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9. [DOI: 10.1038/ni1213] [Cited by in Crossref: 389] [Cited by in F6Publishing: 339] [Article Influence: 22.9] [Reference Citation Analysis]
286 Chan MS, Chen SF, Felizola SJ, Wang L, Nemoto N, Tamaki K, Ishida T, Chow LW, Ohuchi N, Sasano H. Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients. Int J Biol Markers 2014;29:e193-203. [PMID: 24803281 DOI: 10.5301/jbm.5000082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
287 Büchau AS, Morizane S, Trowbridge J, Schauber J, Kotol P, Bui JD, Gallo RL. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol. 2010;184:369-378. [PMID: 19949065 DOI: 10.4049/jimmunol.0902110] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
288 Rozková D, Tiserová H, Fucíková J, Last'ovicka J, Podrazil M, Ulcová H, Budínský V, Prausová J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol 2009;131:1-10. [PMID: 19201656 DOI: 10.1016/j.clim.2009.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
289 Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol 2017;15:465-78. [PMID: 28529325 DOI: 10.1038/nrmicro.2017.44] [Cited by in Crossref: 205] [Cited by in F6Publishing: 176] [Article Influence: 41.0] [Reference Citation Analysis]
290 Song KH, Kim JH, Lee YH, Bae HC, Lee HJ, Woo SR, Oh SJ, Lee KM, Yee C, Kim BW, Cho H, Chung EJ, Chung JY, Hewitt SM, Chung TW, Ha KT, Bae YK, Mao CP, Yang A, Wu TC, Kim TW. Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. J Clin Invest 2018;128:4098-114. [PMID: 30124467 DOI: 10.1172/JCI96804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
291 Gao L, Chen Y. Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). Biomed Rep 2021;15:84. [PMID: 34512972 DOI: 10.3892/br.2021.1460] [Reference Citation Analysis]
292 Hua W, Yuan A, Zheng W, Li C, Cui J, Pang Z, Zhang L, Li Z, Goll R, Cui G. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas. Pathology - Research and Practice 2016;212:106-12. [DOI: 10.1016/j.prp.2015.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
293 Bonfiglio R, Nardozi D, Scimeca M, Cerroni C, Mauriello A, Bonanno E. PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy. Future Oncology 2017;13:2129-31. [DOI: 10.2217/fon-2017-0278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
294 Crespi BJ, Summers K. Positive selection in the evolution of cancer. Biol Rev Camb Philos Soc 2006;81:407-24. [PMID: 16762098 DOI: 10.1017/S1464793106007056] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
295 Grant M, Bollard CM. Developing T-cell therapies for lymphoma without receptor engineering. Blood Adv 2017;1:2579-90. [PMID: 29296911 DOI: 10.1182/bloodadvances.2017009886] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
296 Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138:1429-1440. [PMID: 19909745 DOI: 10.1053/j.gastro.2009.10.057] [Cited by in Crossref: 209] [Cited by in F6Publishing: 188] [Article Influence: 16.1] [Reference Citation Analysis]
297 Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 2017;27:96-108. [PMID: 27981969 DOI: 10.1038/cr.2016.149] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 27.3] [Reference Citation Analysis]
298 Galluzzi L, Rudqvist NP. Preface: More than two decades of modern tumor immunology. Methods Enzymol 2020;631:xxiii-xlii. [PMID: 31948570 DOI: 10.1016/S0076-6879(20)30020-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Wang B, Zhong JL, Li HZ, Wu B, Sun DF, Jiang N, Shang J, Chen YF, Xu XH, Lu HD. Diagnostic and therapeutic values of PMEPA1 and its correlation with tumor immunity in pan-cancer. Life Sci 2021;277:119452. [PMID: 33831430 DOI: 10.1016/j.lfs.2021.119452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015;15:405-14. [PMID: 26027717 DOI: 10.1038/nri3845] [Cited by in Crossref: 509] [Cited by in F6Publishing: 491] [Article Influence: 72.7] [Reference Citation Analysis]
301 Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006;6:146-55. [PMID: 16491074 DOI: 10.1038/nrc1804] [Cited by in Crossref: 235] [Cited by in F6Publishing: 209] [Article Influence: 14.7] [Reference Citation Analysis]
302 Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer 2020;1:46-58. [PMID: 34368780 DOI: 10.1038/s43018-019-0003-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 8.7] [Reference Citation Analysis]
303 Waugh KA, Leach SM, Slansky JE. Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. Vaccines (Basel) 2015;3:771-802. [PMID: 26393659 DOI: 10.3390/vaccines3030771] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
304 Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011;60:319-326. [PMID: 21267721 DOI: 10.1007/s00262-010-0968-0] [Cited by in Crossref: 223] [Cited by in F6Publishing: 185] [Article Influence: 20.3] [Reference Citation Analysis]
305 Hu J, Hu J, Liu X, Hu C, Li M, Han W. Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis. Medicine (Baltimore) 2017;96:e8310. [PMID: 29049237 DOI: 10.1097/MD.0000000000008310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
306 Selleri S, Rumio C, Sabatino M, Marincola FM, Wang E. Tumor Microenvironment and the Immune Response. Surgical Oncology Clinics of North America 2007;16:737-53. [DOI: 10.1016/j.soc.2007.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
307 Jaime-Sanchez P, Uranga-Murillo I, Aguilo N, Khouili SC, Arias MA, Sancho D, Pardo J. Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens. J Immunother Cancer 2020;8:e000528. [PMID: 32241808 DOI: 10.1136/jitc-2020-000528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
308 Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017;9. [PMID: 28490665 DOI: 10.1126/scitranslmed.aal3604] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 61.8] [Reference Citation Analysis]
309 Khajanchi S, Nieto JJ. Mathematical modeling of tumor-immune competitive system, considering the role of time delay. Applied Mathematics and Computation 2019;340:180-205. [DOI: 10.1016/j.amc.2018.08.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
310 Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Critical Reviews in Oncology/Hematology 2016;103:62-77. [DOI: 10.1016/j.critrevonc.2016.04.020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
311 Dietl J, Engel JB, Wischhusen J. The role of regulatory T cells in ovarian cancer. Int J Gynecol Cancer 2007;17:764-70. [PMID: 17309663 DOI: 10.1111/j.1525-1438.2006.00861.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
312 Jukić T, Jurin Martić A, Ivanković S, Antica M, Pavan Jukić D, Rotim C, Jurin M. The role of regulatory T lymphocytes in immune control of MC-2 fibrosarcoma. Acta Clin Croat 2020;59:351-8. [PMID: 33456124 DOI: 10.20471/acc.2020.59.02.20] [Reference Citation Analysis]
313 Ai R, Tao Y, Hao Y, Jiang L, Dan H, Ji N, Zeng X, Zhou Y, Chen Q. Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. Oncotarget 2017;8:81617-35. [PMID: 29113419 DOI: 10.18632/oncotarget.20312] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
314 Davola ME, Vito A, Wei J, El-Sayes N, Workenhe S, Mossman KL. Genetic modification of oncolytic viruses to enhance antitumor immunity. Methods Enzymol 2020;635:231-50. [PMID: 32122548 DOI: 10.1016/bs.mie.2019.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
315 Zha H, Jiang Y, Wang X, Shang J, Wang N, Yu L, Zhao W, Li Z, An J, Zhang X, Chen H, Zhu B, Li Z. Non-canonical PD-1 signaling in cancer and its potential implications in clinic. J Immunother Cancer 2021;9:e001230. [PMID: 33593825 DOI: 10.1136/jitc-2020-001230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
316 Werneck MB, Vieira-de-Abreu A, Chammas R, Viola JP. NFAT1 transcription factor is central in the regulation of tissue microenvironment for tumor metastasis. Cancer Immunol Immunother 2011;60:537-46. [PMID: 21225259 DOI: 10.1007/s00262-010-0964-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
317 Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91. [PMID: 17100877 DOI: 10.1111/j.1600-065X.2006.00457.x] [Cited by in Crossref: 383] [Cited by in F6Publishing: 205] [Article Influence: 25.5] [Reference Citation Analysis]
318 Melo FM, Braga CJ, Pereira FV, Maricato JT, Origassa CS, Souza MF, Melo AC, Silva P, Tomaz SL, Gimenes KP, Scutti JA, Juliano MA, Zamboni DS, Câmara NO, Travassos LR, Ferreira LC, Rodrigues EG. Anti‐metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10. Immunol Cell Biol 2015;93:86-98. [DOI: 10.1038/icb.2014.74] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
319 Babaer D, Zheng M, Ivy MT, Zent R, Tiriveedhi V. Methylselenol producing selenocompounds enhance the efficiency of mammaglobin-A peptide vaccination against breast cancer cells. Oncol Lett 2019;18:6891-8. [PMID: 31807192 DOI: 10.3892/ol.2019.11010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
320 Hernández-lópez E, Núñez-lópez M. Bifurcations in a Cancer and Immune Model with Allee Effect. Int J Bifurcation Chaos 2021;31:2130039. [DOI: 10.1142/s0218127421300391] [Reference Citation Analysis]
321 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med. 2012;60:643-663. [PMID: 22406516 DOI: 10.231/jim.0b013e31824a4d79] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, Galon J, Trajanoski Z. Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother 2012;61:1885-903. [PMID: 22986455 DOI: 10.1007/s00262-012-1354-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
323 Galluzzi L, Rudqvist NP. Preface: More than two decades of modern tumor immunology. Methods Enzymol 2020;636:xvii-xxxvi. [PMID: 32178830 DOI: 10.1016/S0076-6879(20)30114-2] [Reference Citation Analysis]
324 Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Breast Cancer Res Treat 2018;168:135-45. [PMID: 29168063 DOI: 10.1007/s10549-017-4575-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
325 Mlecnik B, Bindea G, Pagès F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30:5-12. [PMID: 21249426 DOI: 10.1007/s10555-011-9270-7] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis]
326 Zhang X, Yang F, Wang Z. Tumor microenvironment characterization in stage IV gastric cancer. Biosci Rep. 2021;41. [PMID: 33416081 DOI: 10.1042/bsr20201248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Biolato AM, Filali L, Wurzer H, Hoffmann C, Gargiulo E, Valitutti S, Thomas C. Actin remodeling and vesicular trafficking at the tumor cell side of the immunological synapse direct evasion from cytotoxic lymphocytes. Int Rev Cell Mol Biol 2020;356:99-130. [PMID: 33066877 DOI: 10.1016/bs.ircmb.2020.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
328 Mallick R, Duttaroy AK. Can interruption of innate immune recognition-mediated emergency myelopoiesis impede tumor progression? Med Hypotheses 2021;155:110663. [PMID: 34403869 DOI: 10.1016/j.mehy.2021.110663] [Reference Citation Analysis]
329 Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol. 2007;179:3472-3479. [PMID: 17804388 DOI: 10.4049/jimmunol.179.6.3472] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 5.9] [Reference Citation Analysis]
330 Malla RR, Kiran P. Tumor microenvironment pathways: Cross regulation in breast cancer metastasis. Genes & Diseases 2020. [DOI: 10.1016/j.gendis.2020.11.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Franco A. CTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens. Scand J Immunol 2005;61:391-7. [PMID: 15882430 DOI: 10.1111/j.1365-3083.2005.01596.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
332 Shklovskaya E, Terry AM, Guy TV, Buckley A, Bolton HA, Zhu E, Holst J, Fazekas de St. Groth B. Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. Immunol Cell Biol 2016;94:593-603. [PMID: 26837456 DOI: 10.1038/icb.2016.14] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
333 Wang S, Liu X, Huang R, Zheng Y, Wang N, Yang B, Situ H, Lin Y, Wang Z. XIAOPI Formula Inhibits Breast Cancer Stem Cells via Suppressing Tumor-Associated Macrophages/C-X-C Motif Chemokine Ligand 1 Pathway. Front Pharmacol 2019;10:1371. [PMID: 31803057 DOI: 10.3389/fphar.2019.01371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
334 Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer 2016;16:759-73. [PMID: 27687979 DOI: 10.1038/nrc.2016.91] [Cited by in Crossref: 162] [Cited by in F6Publishing: 147] [Article Influence: 27.0] [Reference Citation Analysis]
335 Holmström MO, Andersen MH. Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens. Cancers (Basel) 2020;12:E3045. [PMID: 33086698 DOI: 10.3390/cancers12103045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
336 Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 2017;31:1108-16. [PMID: 27890936 DOI: 10.1038/leu.2016.360] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 19.7] [Reference Citation Analysis]
337 Iscaro A, Howard NF, Muthana M. Nanoparticles: Properties and Applications in Cancer Immunotherapy. Curr Pharm Des 2019;25:1962-79. [PMID: 31566122 DOI: 10.2174/1381612825666190708214240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
338 Karthaus N, Torensma R, Tel J. Deciphering the message broadcast by tumor-infiltrating dendritic cells. Am J Pathol. 2012;181:733-742. [PMID: 22796439 DOI: 10.1016/j.ajpath.2012.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
339 Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thörn M, Winqvist O. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 2006;94:1478-84. [PMID: 16641897 DOI: 10.1038/sj.bjc.6603126] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
340 Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2006;55:891-9. [DOI: 10.1007/s00262-005-0085-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 4.0] [Reference Citation Analysis]
341 Nesbeth Y, Conejo-Garcia JR. Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin Dev Immunol 2010;2010:139304. [PMID: 21076522 DOI: 10.1155/2010/139304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
342 Marliot F, Lafontaine L, Galon J. Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. Methods Enzymol 2020;636:109-28. [PMID: 32178816 DOI: 10.1016/bs.mie.2019.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
343 Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci 2016;73:1569-89. [DOI: 10.1007/s00018-016-2135-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
344 Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007;19:203-8. [PMID: 17292599 DOI: 10.1016/j.coi.2007.02.001] [Cited by in Crossref: 202] [Cited by in F6Publishing: 181] [Article Influence: 13.5] [Reference Citation Analysis]
345 Srivastava N, Srivastava PK. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS One 2009;4:e6094. [PMID: 19593447 DOI: 10.1371/journal.pone.0006094] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
346 Zobalova R, Prokopova K, Stantic M, Stapelberg M, Dong L, Ralph SJ, Akporiaye E, Neuzil J. The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection? Antioxidants & Redox Signaling 2011;15:2989-3002. [DOI: 10.1089/ars.2010.3785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
347 Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, Kuo AH, McKenna K, Kojima Y, Leeper NJ, Ho P, Gip P, Swigut T, Sherwood RI, Clarke MF, Somlo G, Young RA, Weissman IL. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat Commun 2017;8:14802. [PMID: 28378740 DOI: 10.1038/ncomms14802] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 16.6] [Reference Citation Analysis]
348 Loustau M, Anna F, Dréan R, Lecomte M, Langlade-Demoyen P, Caumartin J. HLA-G Neo-Expression on Tumors. Front Immunol 2020;11:1685. [PMID: 32922387 DOI: 10.3389/fimmu.2020.01685] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
349 Zhang W, An M, Xi J, Liu H. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy. Bioconjug Chem 2017;28:1993-2000. [PMID: 28644608 DOI: 10.1021/acs.bioconjchem.7b00313] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
350 Samiei H, Sadighi-Moghaddam B, Mohammadi S, Gharavi A, Abdolmaleki S, Khosravi A, Kokhaei P, Bazzazi H, Memarian A. Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21. Immunol Res 2019;67:212-22. [PMID: 31278653 DOI: 10.1007/s12026-019-09079-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
351 Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. J Immunother Cancer 2021;9:e002128. [PMID: 33741731 DOI: 10.1136/jitc-2020-002128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
352 Chavez-Dominguez R, Perez-Medina M, Aguilar-Cazares D, Galicia-Velasco M, Meneses-Flores M, Islas-Vazquez L, Camarena A, Lopez-Gonzalez JS. Old and New Players of Inflammation and Their Relationship With Cancer Development. Front Oncol 2021;11:722999. [PMID: 34881173 DOI: 10.3389/fonc.2021.722999] [Reference Citation Analysis]
353 Odunsi K, Sabbatini P. Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 2008;59:62-74. [PMID: 18154597 DOI: 10.1111/j.1600-0897.2007.00560.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
354 Han J, Rosenzweig SD, Church JA, Holland SM, Ross LA. Variable Presentation of Disseminated Nontuberculous Mycobacterial Infections in a Family with an Interferon-  Receptor Mutation. Clinical Infectious Diseases 2004;39:868-70. [DOI: 10.1086/423804] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
355 Hoffmann MM, Slansky JE. T-cell receptor affinity in the age of cancer immunotherapy. Mol Carcinog 2020;59:862-70. [PMID: 32386086 DOI: 10.1002/mc.23212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
356 Dwarakanath BS, Farooque A, Gupta S. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects. Cancer Rep (Hoboken) 2018;1:e21105. [PMID: 32729245 DOI: 10.1002/cnr2.1105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
357 Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother 2007;56:1037-46. [PMID: 17149595 DOI: 10.1007/s00262-006-0257-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
358 Walshaw RC, Honeychurch J, Illidge TM, Choudhury A. The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. Nat Rev Urol 2018;15:251-9. [PMID: 29089607 DOI: 10.1038/nrurol.2017.172] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
359 Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2020;47:1127-36. [PMID: 31502013 DOI: 10.1007/s00259-019-04500-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
360 Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother 2008;31:7-17. [PMID: 18157007 DOI: 10.1097/CJI.0b013e318159f797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
361 Riccardo F, Bolli E, Macagno M, Arigoni M, Cavallo F, Quaglino E. Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. Curr Top Microbiol Immunol 2017;405:99-122. [PMID: 25294003 DOI: 10.1007/82_2014_426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
362 Ragonnaud E, Holst P. The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Ther Adv Vaccines 2013;1:33-47. [PMID: 24757514 DOI: 10.1177/2051013613480446] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
363 Hasaart KAL, Bertrums EJM, Manders F, Goemans BF, van Boxtel R. Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view. Expert Rev Mol Med 2021;23:e5. [PMID: 33902785 DOI: 10.1017/erm.2021.6] [Reference Citation Analysis]
364 Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, Mpoy C, Arthur CD, Kohlmiller HN, Jacks T, Artyomov MN, Rogers BE, Schreiber RD. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A 2021;118:e2102611118. [PMID: 34099555 DOI: 10.1073/pnas.2102611118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
365 Patil PD, Burotto M, Velcheti V. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Expert Rev Mol Diagn 2018;18:297-305. [PMID: 29430978 DOI: 10.1080/14737159.2018.1440209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
366 Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, Huang L. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther 2013;21:1919-29. [PMID: 23774794 DOI: 10.1038/mt.2013.135] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 12.4] [Reference Citation Analysis]
367 Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie. 2008;90:173-180. [PMID: 17716803 DOI: 10.1016/j.biochi.2007.07.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
368 Holmström MO, Hasselbalch HC, Andersen MH. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers (Basel) 2020;12:E1763. [PMID: 32630667 DOI: 10.3390/cancers12071763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
369 Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005;65:10569-77. [PMID: 16288050 DOI: 10.1158/0008-5472.CAN-05-2117] [Cited by in Crossref: 73] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
370 Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-1570. [PMID: 21436444 DOI: 10.1126/science.1203486] [Cited by in Crossref: 3226] [Cited by in F6Publishing: 2967] [Article Influence: 293.3] [Reference Citation Analysis]
371 Vogt G. How to minimize formation and growth of tumours: potential benefits of decapod crustaceans for cancer research. Int J Cancer 2008;123:2727-34. [PMID: 18823008 DOI: 10.1002/ijc.23947] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
372 Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V. Dendritic cell subsets in health and disease. Immunol Rev. 2007;219:118-142. [PMID: 17850486 DOI: 10.1111/j.1600-065x.2007.00551.x] [Cited by in Crossref: 291] [Cited by in F6Publishing: 138] [Article Influence: 19.4] [Reference Citation Analysis]
373 Shergold AL, Millar R, Nibbs RJ. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research 2019;145:104258. [DOI: 10.1016/j.phrs.2019.104258] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
374 Cho JH. Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. Immune Netw 2017;17:378-91. [PMID: 29302251 DOI: 10.4110/in.2017.17.6.378] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
375 Wurzer H, Hoffmann C, Al Absi A, Thomas C. Actin Cytoskeleton Straddling the Immunological Synapse between Cytotoxic Lymphocytes and Cancer Cells. Cells 2019;8:E463. [PMID: 31100864 DOI: 10.3390/cells8050463] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
376 Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One 2016;11:e0155189. [PMID: 27192170 DOI: 10.1371/journal.pone.0155189] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
377 Baran B, Bechyne I, Siedlar M, Szpak K, Mytar B, Sroka J, Laczna E, Madeja Z, Zembala M, Czyz J. Blood monocytes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factor - alpha. Eur J Cell Biol. 2009;88:743-752. [PMID: 19782426 DOI: 10.1016/j.ejcb.2009.08.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
378 Saw PE, Xu X, Chen J, Song EW. Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci 2021;64:22-50. [PMID: 32930921 DOI: 10.1007/s11427-020-1700-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
379 Kuczma M, Kopij M, Pawlikowska I, Wang CY, Rempala GA, Kraj P. Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells. PLoS One 2010;5:e13623. [PMID: 21049016 DOI: 10.1371/journal.pone.0013623] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
380 d’Onofrio A. A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences. Physica D: Nonlinear Phenomena 2005;208:220-35. [DOI: 10.1016/j.physd.2005.06.032] [Cited by in Crossref: 181] [Cited by in F6Publishing: 79] [Article Influence: 10.6] [Reference Citation Analysis]
381 Apetoh L, Ladoire S, Coukos G, Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 2015;26:1813-23. [PMID: 25922066 DOI: 10.1093/annonc/mdv209] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 18.0] [Reference Citation Analysis]
382 Lee J, Lim K. Growth of HepG2 Cells was Suppressed Through Modulation of STAT6/IL-4 and IL-10 in RAW 264.7 Cells Treated by Phytoglycoprotein (38 kDa). Inflammation 2013;36:549-60. [DOI: 10.1007/s10753-012-9576-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
383 Jiang L, Luo X, Wu D, Zhu S. STOCHASTIC PROPERTIES OF TUMOR GROWTH DRIVEN BY WHITE LÉVY NOISE. Mod Phys Lett B 2012;26:1250149. [DOI: 10.1142/s0217984912501497] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
384 Liang Y, Li L, Chen Y, Xiao J, Wei D. PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression. Clin Chim Acta 2021;519:70-5. [PMID: 33872608 DOI: 10.1016/j.cca.2021.04.010] [Reference Citation Analysis]
385 Fuchs A, Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol 2006;16:359-66. [PMID: 16904340 DOI: 10.1016/j.semcancer.2006.07.002] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 6.1] [Reference Citation Analysis]
386 Kareva I. Immune evasion through competitive inhibition: the shielding effect of cancer non-stem cells. J Theor Biol 2015;364:40-8. [PMID: 25195001 DOI: 10.1016/j.jtbi.2014.08.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
387 Cebon JS, Gore M, Thompson JF, Davis ID, McArthur GA, Walpole E, Smithers M, Cerundolo V, Dunbar PR, MacGregor D, Fisher C, Millward M, Nathan P, Findlay MPN, Hersey P, Evans TRJ, Ottensmeier CH, Marsden J, Dalgleish AG, Corrie PG, Maria M, Brimble M, Williams G, Winkler S, Jackson HM, Endo-Munoz L, Tutuka CSA, Venhaus R, Old LJ, Haack D, Maraskovsky E, Behren A, Chen W. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. J Immunother Cancer 2020;8:e000410. [PMID: 32317292 DOI: 10.1136/jitc-2019-000410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
388 Rahman A, Shashidhara LS. Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal. Cancer Rep (Hoboken) 2021;:e1484. [PMID: 34196131 DOI: 10.1002/cnr2.1484] [Reference Citation Analysis]
389 Bi P, Ruan S. Bifurcations in Delay Differential Equations and Applications to Tumor and Immune System Interaction Models. SIAM J Appl Dyn Syst 2013;12:1847-88. [DOI: 10.1137/120887898] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
390 Augé H, Notarantonio AB, Morizot R, Quinquenel A, Fornecker LM, Hergalant S, Feugier P, Broséus J. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. Front Immunol 2020;11:594841. [PMID: 33381116 DOI: 10.3389/fimmu.2020.594841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
391 Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, Richard F, Delorenzi M, Sotiriou C, Desmedt C, Lorusso G, Rüegg C. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene 2019;38:2814-29. [PMID: 30546090 DOI: 10.1038/s41388-018-0624-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
392 Van den Eynden J, Jiménez-Sánchez A, Miller ML, Larsson E. Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nat Genet 2019;51:1741-8. [PMID: 31768072 DOI: 10.1038/s41588-019-0532-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
393 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
394 Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 2018;6:140. [PMID: 30514385 DOI: 10.1186/s40425-018-0458-z] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 19.3] [Reference Citation Analysis]
395 Ochayon DE, Baranovski BM, Malkin P, Schuster R, Kalay N, Ben-Hamo R, Sloma I, Levinson J, Brazg J, Efroni S, Lewis EC, Nevo U. Experimental Support for the Ecoimmunity Theory: Distinct Phenotypes of Nonlymphocytic Cells in SCID and Wild-Type Mice. Cell Transplant 2016;25:1575-88. [PMID: 26850009 DOI: 10.3727/096368916X690809] [Reference Citation Analysis]
396 Accolla RS, Lombardo L, Abdallah R, Raval G, Forlani G, Tosi G. Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. Front Oncol 2014;4:32. [PMID: 24600588 DOI: 10.3389/fonc.2014.00032] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
397 Jiang L, Luo X, Wu D, Zhu S. Stochastic properties of tumor growth with coupling between non-Gaussian and Gaussian noise terms. Chinese Phys B 2012;21:090503. [DOI: 10.1088/1674-1056/21/9/090503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
398 Barcellos-Hoff MH, Mao JH. HZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary Carcinogenesis. Front Oncol 2016;6:57. [PMID: 27014632 DOI: 10.3389/fonc.2016.00057] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
399 D'Arrigo P, Tufano M, Rea A, Vigorito V, Novizio N, Russo S, Romano MF, Romano S. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Curr Med Chem 2020;27:2402-48. [PMID: 30398102 DOI: 10.2174/0929867325666181106114421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
400 Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y, van Vliet SJ. Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. Front Oncol 2018;8:39. [PMID: 29527514 DOI: 10.3389/fonc.2018.00039] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
401 Ribas A. Immunoediting the cancer genome--a new approach for personalized cancer therapy? Pigment Cell Melanoma Res 2012;25:297-8. [PMID: 22629569 DOI: 10.1111/j.1755-148x.2012.01001.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
402 Seth S, Ager A, Arends MJ, Frayling IM. Lynch syndrome - cancer pathways, heterogeneity and immune escape. J Pathol 2018;246:129-33. [PMID: 30027543 DOI: 10.1002/path.5139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
403 Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, Finn OJ. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol Immunother 2016;65:771-8. [PMID: 27106024 DOI: 10.1007/s00262-016-1838-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
404 Yoneda A, Jinushi M. T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. Immunotargets Ther 2013;2:135-41. [PMID: 27471694 DOI: 10.2147/ITT.S38296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
405 Ohtani H, Nakayama T, Yoshie O. In situ expression of the CCL20-CCR6 axis in lymphocyte-rich gastric cancer and its potential role in the formation of lymphoid stroma. Pathol Int. 2011;61:645-651. [PMID: 22029675 DOI: 10.1111/j.1440-1827.2011.02717.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
406 Natua S, Dhamdhere SG, Mutnuru SA, Shukla S. Interplay within tumor microenvironment orchestrates neoplastic RNA metabolism and transcriptome diversity. Wiley Interdiscip Rev RNA 2021;:e1676. [PMID: 34109748 DOI: 10.1002/wrna.1676] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
407 Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML. Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Proc Natl Acad Sci U S A 2018;115:E11701-10. [PMID: 30463956 DOI: 10.1073/pnas.1804506115] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 15.8] [Reference Citation Analysis]
408 Richardson TE, Shen ZJ, Kanchwala M, Xing C, Filatenkov A, Shang P, Barnett S, Abedin Z, Malter JS, Raisanen JM, Burns DK, White CL, Hatanpaa KJ. Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis. J Neuropathol Exp Neurol 2017;76:874-82. [PMID: 28922848 DOI: 10.1093/jnen/nlx072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
409 Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482:400-404. [PMID: 22318521 DOI: 10.1038/nature10755] [Cited by in Crossref: 741] [Cited by in F6Publishing: 672] [Article Influence: 74.1] [Reference Citation Analysis]
410 Dougan M, Dranoff G. Immunotherapy of Cancer. In: Wang R, editor. Innate Immune Regulation and Cancer Immunotherapy. New York: Springer; 2012. pp. 391-414. [DOI: 10.1007/978-1-4419-9914-6_22] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
411 Bu X, Yao Y, Li X. Immune Checkpoint Blockade in Breast Cancer Therapy. Adv Exp Med Biol 2017;1026:383-402. [PMID: 29282694 DOI: 10.1007/978-981-10-6020-5_18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
412 Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013;31:2369-71. [PMID: 23715576 DOI: 10.1200/JCO.2013.49.2157] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
413 Kloor M. Lymphocyte infiltration and prognosis in colorectal cancer. Lancet Oncol 2009;10:840-1. [PMID: 19717085 DOI: 10.1016/S1470-2045(09)70245-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
414 Tran NL, Sitia G. New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance. Hepatobiliary Surg Nutr 2016;5:511-4. [PMID: 28124011 DOI: 10.21037/hbsn.2016.11.08] [Reference Citation Analysis]
415 Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74-95. [PMID: 28025976 DOI: 10.1038/cr.2016.157] [Cited by in Crossref: 240] [Cited by in F6Publishing: 235] [Article Influence: 40.0] [Reference Citation Analysis]
416 Clayton SM, Archard JA, Wagner J, Farwell DG, Bewley AF, Beliveau A, Birkeland A, Rao S, Abouyared M, Belafsky PC, Anderson JD. Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. Stem Cells Dev 2020;29:327-35. [PMID: 31856674 DOI: 10.1089/scd.2019.0197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
417 Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo) 2018;73:e557s. [PMID: 30540123 DOI: 10.6061/clinics/2018/e557s] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 11.3] [Reference Citation Analysis]
418 Paco L, Garcia-lora AM, Casares C, Cabrera C, Algarra I, Collado A, Maleno I, Garrido F, Lopez-nevot MA. Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. Int J Cancer 2007;121:2023-30. [DOI: 10.1002/ijc.22925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
419 Djafarzadeh R, Noessner E, Engelmann H, Schendel DJ, Notohamiprodjo M, von Luettichau I, Nelson PJ. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 2006;25:1496-508. [PMID: 16261161 DOI: 10.1038/sj.onc.1209188] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
420 Hong B, Li H, Lu Y, Zhang M, Zheng Y, Qian J, Yi Q. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Mol Cancer 2014;13:132. [PMID: 24884733 DOI: 10.1186/1476-4598-13-132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
421 Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 2011;33:335-40. [PMID: 21461991 DOI: 10.1007/s00281-011-0264-x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
422 Rudge G, Barrett SP, Scott B, van Driel IR. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol 2007;178:4089-96. [PMID: 17371963 DOI: 10.4049/jimmunol.178.7.4089] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
423 Kim JH. Interleukin-8 in the Tumor Immune Niche: Lessons from Comparative Oncology. Adv Exp Med Biol 2020;1240:25-33. [PMID: 32060885 DOI: 10.1007/978-3-030-38315-2_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
424 Wattenberg MM, Beatty GL. Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Semin Cancer Biol 2020;65:38-50. [PMID: 31954172 DOI: 10.1016/j.semcancer.2020.01.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
425 Fujiyama T, Oze I, Yagi H, Hashizume H, Matsuo K, Hino R, Kamo R, Imayama S, Hirakawa S, Ito T, Takigawa M, Tokura Y. Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization. J Dermatol Sci 2014;75:43-8. [PMID: 24802712 DOI: 10.1016/j.jdermsci.2014.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
426 Pham TD, Narasimhan V, Guerra G, Kong J, Desai J, Ramsay R, Heriot A. Wither surgical oncology? ANZ J Surg 2019;89:10-1. [PMID: 30756491 DOI: 10.1111/ans.14758] [Reference Citation Analysis]
427 Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebæk E, Andersen MH, Straten Pt, Svane IM. Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol 2013;133:545-52. [PMID: 23014345 DOI: 10.1038/jid.2012.336] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
428 Dzinic SH, Bernardo MM, Oliveira DS, Wahba M, Sakr W, Sheng S. Tumor suppressor maspin as a modulator of host immune response to cancer. Bosn J Basic Med Sci 2015;15:1-6. [PMID: 26614844 DOI: 10.17305/bjbms.2015.783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
429 Germenis AE, Karanikas V. Immunoepigenetics: the unseen side of cancer immunoediting. Immunol Cell Biol 2007;85:55-9. [PMID: 17130900 DOI: 10.1038/sj.icb.7100006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
430 Fry TJ, Lankester AC. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology? Hematol Oncol Clin North Am 2010;24:109-27. [PMID: 20113898 DOI: 10.1016/j.hoc.2009.11.010] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
431 Wischhusen J, Waschbisch A, Wiendl H. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Biol 2007;17:459-68. [PMID: 17768067 DOI: 10.1016/j.semcancer.2007.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
432 Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015;33:23-35. [PMID: 25621841 DOI: 10.1016/j.coi.2015.01.006] [Cited by in Crossref: 226] [Cited by in F6Publishing: 207] [Article Influence: 32.3] [Reference Citation Analysis]
433 Bhutia SK, Mallick SK, Maiti TK. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int 2010;34:553-63. [DOI: 10.1042/cbi20090206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
434 Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11160-11181 [PMID: 25170202 DOI: 10.3748/wjg.v20.i32.11160] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 78] [Article Influence: 9.1] [Reference Citation Analysis]
435 Lollini PL, De Giovanni C, Nanni P. Preclinical HER-2 Vaccines: From Rodent to Human HER-2. Front Oncol 2013;3:151. [PMID: 23772419 DOI: 10.3389/fonc.2013.00151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
436 Knocke S, Fleischmann-Mundt B, Saborowski M, Manns MP, Kühnel F, Wirth TC, Woller N. Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. Cell Rep 2016;17:2234-46. [PMID: 27880900 DOI: 10.1016/j.celrep.2016.10.086] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
437 Nagamine CM, Sohn JJ, Rickman BH, Rogers AB, Fox JG, Schauer DB. Helicobacter hepaticus infection promotes colon tumorigenesis in the BALB/c-Rag2(-/-) Apc(Min/+) mouse. Infect Immun 2008;76:2758-66. [PMID: 18411292 DOI: 10.1128/IAI.01604-07] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
438 Ku GY. The Current Status of Immunotherapies in Esophagogastric Cancer. Hematol Oncol Clin North Am 2019;33:323-38. [PMID: 30833003 DOI: 10.1016/j.hoc.2018.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
439 Cassard L, Cohen-Solal JF, Fournier EM, Camilleri-Broët S, Spatz A, Chouaïb S, Badoual C, Varin A, Fisson S, Duvillard P, Boix C, Loncar SM, Sastre-Garau X, Houghton AN, Avril MF, Gresser I, Fridman WH, Sautès-Fridman C. Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer 2008;123:2832-9. [PMID: 18798552 DOI: 10.1002/ijc.23870] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
440 Kalousková B, Skořepa O, Cmunt D, Abreu C, Krejčová K, Bláha J, Sieglová I, Král V, Fábry M, Pola R, Pechar M, Vaněk O. Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells. Biomedicines 2021;9:1597. [PMID: 34829829 DOI: 10.3390/biomedicines9111597] [Reference Citation Analysis]
441 Haffner MC, Berlato C, Doppler W. Exploiting Our Knowledge of NF-κB Signaling for the Treatment of Mammary Cancer. J Mammary Gland Biol Neoplasia 2006;11:63-73. [DOI: 10.1007/s10911-006-9013-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
442 Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R, Marsigliante S, Maffia M, Lorusso V. Ovarian cancer biomarkers: a focus on genomic and proteomic findings. Curr Genomics 2007;8:335-42. [PMID: 19384429 DOI: 10.2174/138920207782446142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
443 Brandau S. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes. J Urol 2009;181:1532-3. [PMID: 19230928 DOI: 10.1016/j.juro.2009.01.066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
444 Jacqueline C, Bourfia Y, Hbid H, Sorci G, Thomas F, Roche B. Interactions between immune challenges and cancer cells proliferation: timing does matter! Evol Med Public Health 2016;2016:299-311. [PMID: 27535084 DOI: 10.1093/emph/eow025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
445 Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol 2020;1248:7-32. [PMID: 32185705 DOI: 10.1007/978-981-15-3266-5_2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
446 Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, Ji T, Zhang H, Dong W, Jin X, Chen D, Li Y, Zhang S, Xie HQ, Zhao B, Zhao T, Lu J, Hu ZW, Cao X, Qin FX, Huang B. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells. Nat Commun 2017;8:15207. [PMID: 28488695 DOI: 10.1038/ncomms15207] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 14.0] [Reference Citation Analysis]
447 Zheng T, Pierre-Pierre N, Yan X, Huo Q, Almodovar AJ, Valerio F, Rivera-Ramirez I, Griffith E, Decker DD, Chen S, Zhu N. Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment. ACS Appl Mater Interfaces. 2015;7:6819-6827. [PMID: 25757512 DOI: 10.1021/acsami.5b00371] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 11.9] [Reference Citation Analysis]
448 Bhatia A, Kumar Y. Cancer-immune equilibrium: questions unanswered. Cancer Microenviron. 2011;4:209-217. [PMID: 21607751 DOI: 10.1007/s12307-011-0065-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
449 El Sissy C, Marliot F, Haicheur N, Kirilovsky A, Scripcariu D, Lagorce-pagès C, Galon J, Pagès F. Mise au point sur l’Immunoscore et ses potentielles implications cliniques. Annales de Pathologie 2017;37:29-38. [DOI: 10.1016/j.annpat.2016.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
450 Zhang Z, Zhou B, Zhang J, Chen Y, Lai T, Yan L, Liang A, Li Y, Wang Y, Chen Y, Zhang L, Xi MR. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet Cytogenet. 2010;196:146-152. [PMID: 20082850 DOI: 10.1016/j.cancergencyto.2009.09.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
451 Ward JP, Gubin MM, Schreiber RD. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Adv Immunol 2016;130:25-74. [PMID: 26922999 DOI: 10.1016/bs.ai.2016.01.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 17.2] [Reference Citation Analysis]
452 Hashemzadeh N, Adibkia K, Barar J. Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities. Bioimpacts 2019;9:1-3. [PMID: 30788254 DOI: 10.15171/bi.2019.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
453 Garrido C, Algarra I, Maleno I, Stefanski J, Collado A, Garrido F, Garcia-lora AM. Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother 2010;59:13-26. [DOI: 10.1007/s00262-009-0716-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
454 Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008;3:e1983. [PMID: 18431473 DOI: 10.1371/journal.pone.0001983] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 5.8] [Reference Citation Analysis]
455 Sheng W, Huang L. Cancer Immunotherapy and Nanomedicine. Pharm Res 2011;28:200-14. [DOI: 10.1007/s11095-010-0258-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
456 Benoit-Lizon I, Apetoh L. Harnessing TH9 cells in cancer immunotherapy. Semin Immunol 2021;:101477. [PMID: 33893025 DOI: 10.1016/j.smim.2021.101477] [Reference Citation Analysis]
457 Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY, Ye YB. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS One 2013;8:e69044. [PMID: 23935919 DOI: 10.1371/journal.pone.0069044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
458 Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005;117:248-55. [DOI: 10.1002/ijc.21163] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 5.9] [Reference Citation Analysis]
459 Farooque A, Mathur R, Verma A, Kaul V, Bhatt AN, Adhikari JS, Afrin F, Singh S, Dwarakanath BS. Low-dose radiation therapy of cancer: role of immune enhancement. Expert Rev Anticancer Ther 2011;11:791-802. [PMID: 21554054 DOI: 10.1586/era.10.217] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
460 Nicolini A, Carpi A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 2009;29:436-71. [PMID: 19105214 DOI: 10.1002/med.20143] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
461 Canderan G, Gruarin P, Montagna D, Fontana R, Campi G, Melloni G, Traversari C, Dellabona P, Casorati G. An efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinoma. PLoS One 2010;5:e12014. [PMID: 20711505 DOI: 10.1371/journal.pone.0012014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
462 Bourque J, Hawiger D. Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo. Antibodies 2022;11:8. [DOI: 10.3390/antib11010008] [Reference Citation Analysis]
463 Capietto A, Martinet L, Cendron D, Fruchon S, Pont F, Fournié J. Phosphoantigens Overcome Human TCRVγ9 + γδ Cell Immunosuppression by TGF-β: Relevance for Cancer Immunotherapy. J I 2010;184:6680-7. [DOI: 10.4049/jimmunol.1000681] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
464 Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013;2:e26836. [PMID: 24498556 DOI: 10.4161/onci.26836] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 8.6] [Reference Citation Analysis]
465 Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256-265. [PMID: 23291374 DOI: 10.1093/jnci/djs629] [Cited by in Crossref: 595] [Cited by in F6Publishing: 581] [Article Influence: 66.1] [Reference Citation Analysis]
466 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Reference Citation Analysis]
467 Tang M, Diao J, Cattral MS. Molecular mechanisms involved in dendritic cell dysfunction in cancer. Cell Mol Life Sci 2017;74:761-76. [PMID: 27491428 DOI: 10.1007/s00018-016-2317-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
468 Esendagli G, Abbasoglu O. Immune system in cancer and hydatid disease: cross-reactivity vs. immune modulation. Parasite Immunol 2015;37:427-8. [DOI: 10.1111/pim.12200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
469 McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 2013;62:773-85. [PMID: 23263452 DOI: 10.1007/s00262-012-1384-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
470 Kaluđerović GN, Krajnović T, Momcilovic M, Stosic-Grujicic S, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. J Inorg Biochem 2015;153:315-21. [PMID: 26428537 DOI: 10.1016/j.jinorgbio.2015.09.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
471 Jung M, Mertens C, Brüne B. Macrophage iron homeostasis and polarization in the context of cancer. Immunobiology 2015;220:295-304. [PMID: 25260218 DOI: 10.1016/j.imbio.2014.09.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
472 Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6:208-223. [PMID: 25830040 DOI: 10.3978/j.issn.2078-6891.2014.077] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
473 Rezaei R, Esmaeili Gouvarchin Ghaleh H, Farzanehpour M, Dorostkar R, Ranjbar R, Bolandian M, Mirzaei Nodooshan M, Ghorbani Alvanegh A. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Cancer Gene Ther 2021. [PMID: 34158626 DOI: 10.1038/s41417-021-00359-9] [Reference Citation Analysis]
474 Iwami S, Haeno H, Michor F. A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol 2012;8:e1002370. [PMID: 22359489 DOI: 10.1371/journal.pcbi.1002370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
475 Meireson A, Ferdinande L, Haspeslagh M, Hennart B, Allorge D, Ost P, Sundahl N, Spaas M, Demeyer A, Brochez L. Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma. Front Immunol 2021;12:736498. [PMID: 34557196 DOI: 10.3389/fimmu.2021.736498] [Reference Citation Analysis]
476 Bignold LP. Embryonic reversions and lineage infidelities in tumour cells: genome-based models and role of genetic instability. Int J Exp Pathol 2005;86:67-79. [PMID: 15810978 DOI: 10.1111/j.0959-9673.2005.00421.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
477 Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens. 2007;70:1-11. [PMID: 17559575 DOI: 10.1111/j.1399-0039.2007.00869.x] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 7.1] [Reference Citation Analysis]
478 Lee YH, Bae HC, Noh KH, Song KH, Ye SK, Mao CP, Lee KM, Wu TC, Kim TW. Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes. Clin Cancer Res 2015;21:1438-46. [PMID: 25589622 DOI: 10.1158/1078-0432.CCR-14-1979] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
479 Valentinuzzi D, Simončič U, Uršič K, Vrankar M, Turk M, Jeraj R. Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Phys Med Biol 2019;64:025017. [DOI: 10.1088/1361-6560/aaf96c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
480 Zamanakou M, Germenis AE, Karanikas V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett. 2007;111:69-75. [PMID: 17644189 DOI: 10.1016/j.imlet.2007.06.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
481 Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumour Biol 2014;35:8483-523. [PMID: 25104089 DOI: 10.1007/s13277-014-2421-z] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 10.1] [Reference Citation Analysis]
482 Messmer MN, Snyder AG, Oberst A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death Differ 2019;26:115-29. [PMID: 30341424 DOI: 10.1038/s41418-018-0214-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
483 Eder K, Kalman B. The Dynamics of Interactions Among Immune and Glioblastoma Cells. Neuromolecular Med 2015;17:335-52. [PMID: 26224516 DOI: 10.1007/s12017-015-8362-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
484 d’Onofrio A. Multifaceted Kinetics of Immuno-Evasion from Tumor Dormancy. In: Enderling H, Almog N, Hlatky L, editors. Systems Biology of Tumor Dormancy. New York: Springer; 2013. pp. 111-43. [DOI: 10.1007/978-1-4614-1445-2_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
485 Urosevic M, Braun B, Willers J, Burg G, Dummer R. Expression of melanoma-associated antigens in melanoma cell cultures. Exp Dermatol 2005;14:491-7. [PMID: 15946236 DOI: 10.1111/j.0906-6705.2005.00305.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
486 Dimitriou N, Felekouras E, Karavokyros I, Alexandrou A, Pikoulis E, Griniatsos J. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. BMC Cancer 2018;18:1202. [PMID: 30509242 DOI: 10.1186/s12885-018-5042-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
487 Zhang L, Xu X, Su X. Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Mol Cancer 2020;19:48. [PMID: 32122338 DOI: 10.1186/s12943-020-01154-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
488 Persson CM, Chambers BJ. Plasmacytoid dendritic cell-induced migration and activation of NK cells in vivo. Eur J Immunol 2010;40:2155-64. [PMID: 20540112 DOI: 10.1002/eji.200940098] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
489 Zumwalt TJ, Goel A. Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. Curr Colorectal Cancer Rep. 2015;11:125-140. [PMID: 26441489 DOI: 10.1007/s11888-015-0269-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
490 Bremnes RM, Donnem T, Busund LT. Importance of tumor infiltrating lymphocytes in non-small cell lung cancer? Ann Transl Med 2016;4:142. [PMID: 27162792 DOI: 10.21037/atm.2016.03.28] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
491 Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer 2020;20:398-411. [PMID: 32488200 DOI: 10.1038/s41568-020-0263-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 24.5] [Reference Citation Analysis]
492 Li Z, Li Y, Gao J, Fu Y, Hua P, Jing Y, Cai M, Wang H, Tong T. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sci 2021;273:119150. [PMID: 33662426 DOI: 10.1016/j.lfs.2021.119150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
493 Gross E, Sunwoo JB, Bui JD. Cancer Immunosurveillance and Immunoediting by Natural Killer Cells. The Cancer Journal 2013;19:483-9. [DOI: 10.1097/ppo.0000000000000005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
494 Kumar A, Watkins R, Vilgelm AE. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. Front Immunol 2021;12:690499. [PMID: 34140957 DOI: 10.3389/fimmu.2021.690499] [Reference Citation Analysis]
495 Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol 2014;10:41-62. [PMID: 24325346 DOI: 10.1586/1744666X.2014.865519] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 7.1] [Reference Citation Analysis]
496 Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006;10:77-87. [DOI: 10.1016/j.ccr.2006.05.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
497 Pereira MB, Barros LRC, Bracco PA, Vigo A, Boroni M, Bonamino MH, Lenz G. Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival. Oncoimmunology 2018;7:e1431083. [PMID: 29872555 DOI: 10.1080/2162402X.2018.1431083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
498 Luby TM. Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Rev Vaccines 2008;7:995-1003. [PMID: 18767949 DOI: 10.1586/14760584.7.7.995] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
499 Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011;30:3477-88. [PMID: 21577205 DOI: 10.1038/onc.2011.160] [Cited by in Crossref: 169] [Cited by in F6Publishing: 156] [Article Influence: 15.4] [Reference Citation Analysis]
500 Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel) 2020;12:E1121. [PMID: 32365838 DOI: 10.3390/cancers12051121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
501 Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res. 2009;69:6978-6986. [PMID: 19706756 DOI: 10.1158/0008-5472.can-09-1101] [Cited by in Crossref: 91] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
502 Janiak MK, Pocięgiel M, Welsh JS. Time to rejuvenate ultra-low dose whole-body radiotherapy of cancer. Crit Rev Oncol Hematol 2021;160:103286. [PMID: 33667656 DOI: 10.1016/j.critrevonc.2021.103286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Mishra R, Chen AT, Welsh RM, Szomolanyi-Tsuda E. NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors. PLoS Pathog 2010;6:e1000924. [PMID: 20523894 DOI: 10.1371/journal.ppat.1000924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
504 Jamieson NB, Mohamed M, Oien KA, Foulis AK, Dickson EJ, Imrie CW, Carter CR, Mckay CJ, Mcmillan DC. The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2012;19:3581-90. [DOI: 10.1245/s10434-012-2370-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
505 Dai Z, Tian T, Wang M, Liu X, Lin S, Yang P, Liu K, Zheng Y, Xu P, Liu M, Yang X, Dai Z. CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis. PeerJ 2017;5:e2815. [PMID: 28097051 DOI: 10.7717/peerj.2815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
506 Abrams SI, Netherby CS, Twum DY, Messmer MN. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. J Interferon Cytokine Res 2016;36:442-53. [PMID: 27379866 DOI: 10.1089/jir.2015.0174] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
507 Galluzzi L, Rudqvist NP. Preface: More than two decades of modern tumor immunology. Methods Enzymol 2019;629:xxi-xl. [PMID: 31727259 DOI: 10.1016/S0076-6879(19)30459-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
508 Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science 2021;374:1325-6. [PMID: 34882456 DOI: 10.1126/science.abk3436] [Reference Citation Analysis]
509 Nikolaou M, Nikolaou G, Digklia A, Pontas C, Tsoukalas N, Kyrgias G, Tolia M. Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integr Cancer Ther 2019;18:1534735419827090. [PMID: 30791740 DOI: 10.1177/1534735419827090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
510 López-Otín C, Kroemer G. Hallmarks of Health. Cell 2021;184:33-63. [PMID: 33340459 DOI: 10.1016/j.cell.2020.11.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 18.5] [Reference Citation Analysis]
511 Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 2010;22:105-112. [PMID: 20226686 DOI: 10.1016/j.smim.2010.02.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
512 Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 2010;20:1-10. [PMID: 19952852 DOI: 10.1097/cmr.0b013e328333bbc8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
513 Saeed M, Gao J, Shi Y, Lammers T, Yu H. Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. Theranostics 2019;9:7981-8000. [PMID: 31754376 DOI: 10.7150/thno.37568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 15.3] [Reference Citation Analysis]
514 Roeser JC, Leach SD, Mcallister F. Emerging strategies for cancer immunoprevention. Oncogene 2015;34:6029-39. [DOI: 10.1038/onc.2015.98] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
515 Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, Guo C, Tang Y, Zhou Y, Liao Q, Wu X, Wang H, Yu J, Li Y, Li X, Li G, Zeng Z, Tan Y, Xiong W. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res 2021;40:81. [PMID: 33648534 DOI: 10.1186/s13046-021-01874-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
516 Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother 2011;60:419-23. [PMID: 20976448 DOI: 10.1007/s00262-010-0930-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
517 Wilmas KM, Nguyen QB, Patel J, Silapunt S, Migden MR. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol 2021;17:4971-82. [PMID: 34608809 DOI: 10.2217/fon-2021-0901] [Reference Citation Analysis]
518 Li MO, Flavell RA. TGF-β, T-cell tolerance and immunotherapy of autoimmune diseases and cancer. Expert Review of Clinical Immunology 2014;2:257-65. [DOI: 10.1586/1744666x.2.2.257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
519 Rajarubendra N, Lawrentschuk N, Bolton DM, Klotz L, Davis ID. Prostate cancer immunology - an update for Urologists: PROSTATE CANCER IMMUNOLOGY. BJU International 2011;107:1046-51. [DOI: 10.1111/j.1464-410x.2010.09820.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
520 Xiang JF, Liu L. Immune contexture and classification in human digestive malignant tumors: A novel way to evaluate tumors and impact on clinical outcome and therapy. Shijie Huaren Xiaohua Zazhi 2016; 24(25): 3666-3672 [DOI: 10.11569/wcjd.v24.i25.3666] [Reference Citation Analysis]
521 Hayakawa Y. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012;16:587-99. [PMID: 22530569 DOI: 10.1517/14728222.2012.681378] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
522 Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV. Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology 2016;5:e1052213. [PMID: 26942060 DOI: 10.1080/2162402X.2015.1052213] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
523 Marwitz S, Ballesteros-Merino C, Jensen SM, Reck M, Kugler C, Perner S, Drömann D, Goldmann T, Fox BA. Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. J Immunother Cancer 2021;9:e001469. [PMID: 33589523 DOI: 10.1136/jitc-2020-001469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Chien MH, Hsin CH, Chou LS, Chung TT, Lin CH, Weng MS, Chou MY, Chen MK, Yang SF. Interleukin-23 receptor polymorphism as a risk factor for oral cancer susceptibility. Head Neck. 2012;34:551-556. [PMID: 21717520 DOI: 10.1002/hed.21779] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
525 Naganawa K, Takayama E, Adachi M, Mitsudo K, Iida M, Kamiya-Mizuno M, Kawaki H, Ichinose M, Motohashi M, Muramatsu Y, Tohnai I, Sumitomo S, Shikimori M, Kondoh N. Producing Capabilities of Interferon-gamma and Interleukin-10 in Peripheral Blood from Oral Squamous Cell Carcinoma Patients. Open Dent J 2015;9:120-4. [PMID: 25893021 DOI: 10.2174/1874210601509010120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
526 Goldstein MG, Li Z. Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis. J Hematol Oncol 2009;2:5. [PMID: 19183457 DOI: 10.1186/1756-8722-2-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
527 Ouni N, Ben Chaaben A, Kablouti G, Lajnef M, Ayari F, Abaza H, Damak T, Harzallah L, Benammar-elgaaeid A, Guemira F, Tamouza R. MICA-129Met/Val Polymorphism Is Associated with Early-Onset Breast Cancer Risk. Immunological Investigations 2017;46:603-14. [DOI: 10.1080/08820139.2017.1336175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
528 Ledzewicz U, Schättler H. On the Role of the Objective in the Optimization of Compartmental Models for Biomedical Therapies. J Optim Theory Appl 2020;:1-31. [PMID: 33012845 DOI: 10.1007/s10957-020-01754-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
529 Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 2014;92:195-203. [PMID: 24175978 DOI: 10.1111/ejh.12228] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
530 Shi Y, Yu P, Zeng D, Qian F, Lei X, Zhao Y, Tang B, Hao Y, Luo H, Chen J, Tan Y. Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity. FEBS J 2014;281:3882-93. [PMID: 25041128 DOI: 10.1111/febs.12923] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
531 Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH. Are BiTEs the "missing link" in cancer therapy? Oncoimmunology 2015;4:e1008339. [PMID: 26155413 DOI: 10.1080/2162402X.2015.1008339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
532 Varn FS, Mullins DW, Arias-Pulido H, Fiering S, Cheng C. Adaptive immunity programmes in breast cancer. Immunology 2017;150:25-34. [PMID: 27564847 DOI: 10.1111/imm.12664] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
533 Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A, Algarra I, Garrido F, Garcia-Lora AM. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 2012;33:687-93. [PMID: 22219178 DOI: 10.1093/carcin/bgr318] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
534 Matanes E, Gotlieb WH. Immunotherapy of gynecological cancers. Best Pract Res Clin Obstet Gynaecol 2019;60:97-110. [PMID: 31003902 DOI: 10.1016/j.bpobgyn.2019.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
535 Chen Y, Gao XJ, Deng YC, Zhang HX. Relationship between HLA-G gene polymorphism and the susceptibility of esophageal cancer in Kazakh and Han nationality in Xinjiang. Biomarkers. 2012;17:9-15. [PMID: 22080860 DOI: 10.3109/1354750x.2011.633242] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
536 Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 2016;16:131-44. [PMID: 26911188 DOI: 10.1038/nrc.2016.14] [Cited by in Crossref: 409] [Cited by in F6Publishing: 387] [Article Influence: 68.2] [Reference Citation Analysis]
537 Simson L, Ellyard JI, Parish CR. The Role of Th2-Mediated Anti-Tumor Immunity in Tumor Surveillance and Clearance. In: Penichet ML, Jensen-jarolim E, editors. Cancer and IgE. Totowa: Humana Press; 2010. pp. 255-75. [DOI: 10.1007/978-1-60761-451-7_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
538 Foerster F, Boegel S, Heck R, Pickert G, Rüssel N, Rosigkeit S, Bros M, Strobl S, Kaps L, Aslam M, Diken M, Castle J, Sahin U, Tuettenberg A, Bockamp E, Schuppan D. Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. Oncoimmunology 2018;7:e1409929. [PMID: 29632723 DOI: 10.1080/2162402X.2017.1409929] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
539 Mirzaei S, Fekri HS, Hashemi F, Hushmandi K, Mohammadinejad R, Ashrafizadeh M, Zarrabi A, Garg M. Venom peptides in cancer therapy: An updated review on cellular and molecular aspects. Pharmacol Res 2021;164:105327. [PMID: 33276098 DOI: 10.1016/j.phrs.2020.105327] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
540 Santos C, Ferreirinha P, Sousa H, Ribeiro J, Bastos MM, Neto T, Oliveira PA, Medeiros R, Vilanova M, Gil da Costa RM. Ptaquiloside from bracken (Pteridium spp.) inhibits tumour-infiltrating CD8+ T cells in HPV-16 transgenic mice. Food and Chemical Toxicology 2016;97:277-85. [DOI: 10.1016/j.fct.2016.09.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
541 Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205:825-39. [PMID: 18362171 DOI: 10.1084/jem.20071341] [Cited by in Crossref: 262] [Cited by in F6Publishing: 238] [Article Influence: 18.7] [Reference Citation Analysis]
542 Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. Ann N Y Acad Sci 2021;1499:18-41. [PMID: 32445205 DOI: 10.1111/nyas.14377] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
543 Césaire M, Thariat J, Candéias SM, Stefan D, Saintigny Y, Chevalier F. Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer? Int J Mol Sci 2018;19:E3793. [PMID: 30487462 DOI: 10.3390/ijms19123793] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
544 Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res. 2014;74:2663-2668. [PMID: 24778417 DOI: 10.1158/0008-5472.can-14-0301] [Cited by in Crossref: 91] [Cited by in F6Publishing: 58] [Article Influence: 11.4] [Reference Citation Analysis]
545 Rubin B. Natural immunity has significant impact on immune responses against cancer. Scand J Immunol. 2009;69:275-290. [PMID: 19281540 DOI: 10.1111/j.1365-3083.2008.02220.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
546 Alvarez RF, Barbuto JAM, Venegeroles R. A nonlinear mathematical model of cell-mediated immune response for tumor phenotypic heterogeneity. J Theor Biol 2019;471:42-50. [PMID: 30930063 DOI: 10.1016/j.jtbi.2019.03.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
547 de Kruijf EM, Engels CC, van de Water W, Bastiaannet E, Smit VTHBM, van de Velde CJH, Liefers GJ, Kuppen PJK. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat 2013;142:355-64. [DOI: 10.1007/s10549-013-2752-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
548 Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif 2008;41:960-79. [PMID: 19040572 DOI: 10.1111/j.1365-2184.2008.00558.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.6] [Reference Citation Analysis]
549 Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol 2016;28:373-82. [PMID: 27121213 DOI: 10.1093/intimm/dxw021] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 15.5] [Reference Citation Analysis]
550 Crespi B, Summers K. Evolutionary biology of cancer. Trends Ecol Evol 2005;20:545-52. [PMID: 16701433 DOI: 10.1016/j.tree.2005.07.007] [Cited by in Crossref: 163] [Cited by in F6Publishing: 134] [Article Influence: 9.6] [Reference Citation Analysis]
551 Banach M, Robert J. Tumor immunology viewed from alternative animal models-the Xenopus story. Curr Pathobiol Rep 2017;5:49-56. [PMID: 28944105 DOI: 10.1007/s40139-017-0125-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
552 Nagl S, Haas M, Lahmer G, Büttner-Herold M, Grabenbauer GG, Fietkau R, Distel LV. Cell-to-cell distances between tumor-infiltrating inflammatory cells have the potential to distinguish functionally active from suppressed inflammatory cells. Oncoimmunology 2016;5:e1127494. [PMID: 27467940 DOI: 10.1080/2162402X.2015.1127494] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
553 Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med 2016;67:165-83. [PMID: 26332003 DOI: 10.1146/annurev-med-051914-021702] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 10.9] [Reference Citation Analysis]
554 Nicolini A, Rossi G, Ferrari P, Morganti R, Carpi A. A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. J Mol Med 2020;98:375-82. [DOI: 10.1007/s00109-020-01881-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
555 Deutsch É, Lévy A, Chargari C. [Radiation therapy and immunomodulation: Focus on experimental data]. Cancer Radiother 2015;19:515-8. [PMID: 26293415 DOI: 10.1016/j.canrad.2015.05.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
556 Sun D, Zhang J, Wang L, Yu Z, O'Driscoll CM, Guo J. Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy. Drug Discov Today 2021;26:651-62. [PMID: 33278602 DOI: 10.1016/j.drudis.2020.11.029] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
557 da Gama Duarte J, Woods K, Andrews MC, Behren A. The good, the (not so) bad and the ugly of immune homeostasis in melanoma. Immunol Cell Biol 2018;96:497-506. [PMID: 29392770 DOI: 10.1111/imcb.12001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
558 Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, Parsa AT. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 2010;17:1381-5. [PMID: 20727764 DOI: 10.1016/j.jocn.2010.03.031] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 7.3] [Reference Citation Analysis]
559 Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int. 2013;13:92. [PMID: 24025698 DOI: 10.1186/1475-2867-13-92] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 9.9] [Reference Citation Analysis]
560 Sivagnanalingam U, Beatty PL, Finn OJ. Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention. Mol Carcinog 2020;59:852-61. [PMID: 32333615 DOI: 10.1002/mc.23206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
561 Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book 2019;39:147-64. [PMID: 31099674 DOI: 10.1200/EDBK_240837] [Cited by in Crossref: 187] [Cited by in F6Publishing: 129] [Article Influence: 62.3] [Reference Citation Analysis]
562 Kissick HT. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer. Cold Spring Harb Perspect Biol 2018;10:a033704. [PMID: 29254981 DOI: 10.1101/cshperspect.a033704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
563 Collin JF, Wells JW, Czepulkowski B, Lyne L, Duriez PJ, Banham AH, Mufti GJ, Guinn BA. A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells. Genes Chromosomes Cancer 2015;54:288-302. [PMID: 25706801 DOI: 10.1002/gcc.22242] [Reference Citation Analysis]
564 Rolfo C, Sortino G, Smits E, Passiglia F, Bronte G, Castiglia M, Russo A, Santos ES, Janssens A, Pauwels P, Raez L. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? Expert Rev Anticancer Ther 2014;14:1173-87. [PMID: 25148289 DOI: 10.1586/14737140.2014.952287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
565 Yang P, Ma J, Yang X, Li W. Peripheral CD4+ naïve/memory ratio is an independent predictor of survival in non-small cell lung cancer. Oncotarget 2017;8:83650-9. [PMID: 29137371 DOI: 10.18632/oncotarget.19330] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
566 Wakita D, Chamoto K, Ohkuri T, Narita Y, Ashino S, Sumida K, Nishikawa H, Shiku H, Togashi Y, Kitamura H, Nishimura T. IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009;30:1408-15. [PMID: 19509217 DOI: 10.1093/carcin/bgp144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
567 Wang E, Tomei S, Marincola FM. Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother 2012;61:761-70. [PMID: 22576055 DOI: 10.1007/s00262-012-1274-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
568 Vlad AM, Diaconu I, Gantt KR. MUC1 in endometriosis and ovarian cancer. Immunol Res 2006;36:229-36. [PMID: 17337783 DOI: 10.1385/IR:36:1:229] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
569 Li Z, Wu Y, Wang C, Zhang M. Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. Cancer Immunol Immunother 2019;68:1303-15. [PMID: 31278476 DOI: 10.1007/s00262-019-02363-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
570 Thibodeaux SR, Curiel TJ. Immune Therapy for Ovarian Cancer: Promise and Pitfalls. International Reviews of Immunology 2011;30:102-19. [DOI: 10.3109/08830185.2011.567361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
571 Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35 Suppl:S185-S198. [PMID: 25818339 DOI: 10.1016/j.semcancer.2015.03.004] [Cited by in Crossref: 546] [Cited by in F6Publishing: 533] [Article Influence: 78.0] [Reference Citation Analysis]
572 Engels CC, Fontein DB, Kuppen PJ, de Kruijf EM, Smit VT, Nortier JW, Liefers GJ, van de Velde CJ, Bastiaannet E. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. Br J Cancer 2014;111:532-8. [PMID: 24937677 DOI: 10.1038/bjc.2014.338] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
573 Taneichi M, Ishida H, Kajino K, Ogasawara K, Tanaka Y, Kasai M, Mori M, Nishida M, Yamamura H, Mizuguchi J, Uchida T. Antigen Chemically Coupled to the Surface of Liposomes Are Cross-Presented to CD8 + T Cells and Induce Potent Antitumor Immunity. J Immunol 2006;177:2324-30. [DOI: 10.4049/jimmunol.177.4.2324] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
574 Boesch M, Baty F, Rothschild SI, Tamm M, Joerger M, Früh M, Brutsche MH. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021;125:313-23. [PMID: 33824481 DOI: 10.1038/s41416-021-01365-2] [Reference Citation Analysis]
575 Li P, Wang N, Zhang Y, Wang C, Du L. HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers. Front Immunol 2021;12:791535. [PMID: 34868081 DOI: 10.3389/fimmu.2021.791535] [Reference Citation Analysis]
576 Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427-2437. [PMID: 18551193 DOI: 10.1172/jci35017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 219] [Article Influence: 3.4] [Reference Citation Analysis]
577 Tang T, Xue H, Cui S, Gong Z, Fei Z, Cheng S, Gui C. Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese. Fam Cancer. 2014;13:619-623. [PMID: 24861772 DOI: 10.1007/s10689-014-9731-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
578 Martinek J, Wu T, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Immunobiology of Dendritic Cells Part A. Elsevier; 2019. pp. 179-215. [DOI: 10.1016/bs.ircmb.2019.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
579 Barton C, Davies D, Balkwill F, Burke F. Involvement of both intrinsic and extrinsic pathways in IFN-γ-induced apoptosis that are enhanced with cisplatin. European Journal of Cancer 2005;41:1474-86. [DOI: 10.1016/j.ejca.2005.03.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
580 Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 2021;17:213-23. [PMID: 33686279 DOI: 10.1038/s41584-021-00584-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
581 Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res 2021;31:5-16. [PMID: 32733014 DOI: 10.1038/s41422-020-0383-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
582 Bini Dhouib I, Annabi A, Jallouli M, Marzouki S, Gharbi N, Elfazaa S, Montassar Lasram M. Carbamates pesticides induced immunotoxicity and carcinogenicity in human: A review. J Appl Biomed 2016;14:85-90. [DOI: 10.1016/j.jab.2016.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
583 Silaeva YY, Grinenko TS, Vagida MS, Kalinina AA, Khromykh LM, Kazansky DB. Immune selection of tumor cells in TCR β-chain transgenic mice. J Immunotoxicol 2014;11:393-9. [PMID: 24308870 DOI: 10.3109/1547691X.2013.861548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
584 Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto ML, Wang E, Marincola FM, Manjili MH. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011;9:170. [PMID: 21978632 DOI: 10.1186/1479-5876-9-170] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
585 Paladini L, Fabris L, Bottai G, Raschioni C, Calin GA, Santarpia L. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res 2016;35:103. [PMID: 27349385 DOI: 10.1186/s13046-016-0375-2] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 16.5] [Reference Citation Analysis]
586 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014;3:e27878. [PMID: 24800173 DOI: 10.4161/onci.27878] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 12.4] [Reference Citation Analysis]
587 Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, Yasui T, Kikutani H, Shibuya K, Shibuya A. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008;205:2959-64. [PMID: 19029379 DOI: 10.1084/jem.20081611] [Cited by in Crossref: 179] [Cited by in F6Publishing: 165] [Article Influence: 12.8] [Reference Citation Analysis]
588 Nathenson MJ, Conley AP, Sausville E. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 2018;23:71-83. [PMID: 28935774 DOI: 10.1634/theoncologist.2016-0025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
589 Carosella ED, Rouas-freiss N, Roux DT, Moreau P, Lemaoult J. HLA-G. Elsevier; 2015. pp. 33-144. [DOI: 10.1016/bs.ai.2015.04.001] [Cited by in Crossref: 189] [Cited by in F6Publishing: 192] [Article Influence: 27.0] [Reference Citation Analysis]
590 Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, Poutahidis T, Taylor CL, Jackson EA, Hewes C. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev. 2010;19:1153-1166. [PMID: 20199238 DOI: 10.1089/scd.2009.0439] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
591 Zeppellini A, Galimberti S, Leone BE, Pacifico C, Riva F, Cicchiello F, Capici S, Maggioni C, Sala L, Cazzaniga ME. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study. BMC Cancer 2021;21:260. [PMID: 33691674 DOI: 10.1186/s12885-021-07960-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Elsner L, Muppala V, Gehrmann M, Lozano J, Malzahn D, Bickeböller H, Brunner E, Zientkowska M, Herrmann T, Walter L, Alves F, Multhoff G, Dressel R. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 2007;179:5523-33. [PMID: 17911639 DOI: 10.4049/jimmunol.179.8.5523] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 6.1] [Reference Citation Analysis]
593 Polak ME, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: The problems of local immunosuppression. Human Immunology 2009;70:331-9. [DOI: 10.1016/j.humimm.2009.01.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
594 Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A, Selling K, Sherif A, Winqvist O. FOXP3 and survival in urinary bladder cancer. BJU Int. 2011;108:1672-1678. [PMID: 21244603 DOI: 10.1111/j.1464-410x.2010.10020.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
595 Barham W, Gicobi JK, Yan Y, Dronca RS, Dong H. Paradox-driven adventures in the development of cancer immunology and immunotherapy. Genes Dis 2019;6:224-31. [PMID: 32042862 DOI: 10.1016/j.gendis.2019.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
596 Mandarino A, Gregory DJ, McGuire CC, Leblanc BW, Witt H, Rivera LM, Godleski JJ, Fedulov AV. The effect of talc particles on phagocytes in co-culture with ovarian cancer cells. Environ Res 2020;180:108676. [PMID: 31785414 DOI: 10.1016/j.envres.2019.108676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
597 Farahani N, Mohagheghi F, Mosayebi G, Ghazavi A, Ganji A. Reduced IL-37 gene expression and CD8 T lymphocytes in patients with metastatic breast cancer. Breast Dis 2021. [PMID: 34024810 DOI: 10.3233/BD-201055] [Reference Citation Analysis]
598 Vahidian F, Duijf PH, Safarzadeh E, Derakhshani A, Baghbanzadeh A, Baradaran B. Interactions between cancer stem cells, immune system and some environmental components: Friends or foes? Immunology Letters 2019;208:19-29. [DOI: 10.1016/j.imlet.2019.03.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
599 Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 2014;33:1025-41. [PMID: 25359584 DOI: 10.1007/s10555-014-9529-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
600 Ottesen JT, Pedersen RK, Dam MJB, Knudsen TA, Skov V, Kjær L, Andersen M. Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment. Cancers (Basel) 2020;12:E2119. [PMID: 32751766 DOI: 10.3390/cancers12082119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
601 Mempel TR, Bauer CA. Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis. 2009;26:311-327. [PMID: 18665448 DOI: 10.1007/s10585-008-9196-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
602 Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer. 2006;42:751-759. [PMID: 16530403 DOI: 10.1016/j.ejca.2006.01.010] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 7.8] [Reference Citation Analysis]
603 Ho M, Goh CY, Patel A, Staunton S, O'Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clin Lymphoma Myeloma Leuk 2020;20:e752-68. [PMID: 32651110 DOI: 10.1016/j.clml.2020.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
604 Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. The Lancet 2008;371:771-83. [DOI: 10.1016/s0140-6736(08)60241-x] [Cited by in Crossref: 344] [Cited by in F6Publishing: 177] [Article Influence: 24.6] [Reference Citation Analysis]
605 Singh M, Boomsma JJ. Policing and punishment across the domains of social evolution. Oikos 2015;124:971-82. [DOI: 10.1111/oik.02064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
606 Leng Q, Tarbe M, Long Q, Wang F. Pre-existing heterologous T-cell immunity and neoantigen immunogenicity. Clin Transl Immunology. 2020;9:e01111. [PMID: 32211191 DOI: 10.1002/cti2.1111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
607 Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 2010;16:3409-19. [PMID: 20472682 DOI: 10.1158/1078-0432.CCR-10-0644] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
608 Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, Ernstoff MS. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16:5548-5556. [PMID: 20884622 DOI: 10.1158/1078-0432.ccr-10-2138] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
609 Banchereau J, Palucka K. Cancer vaccines on the move. Nat Rev Clin Oncol 2018;15:9-10. [DOI: 10.1038/nrclinonc.2017.149] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 14.6] [Reference Citation Analysis]
610 Sun R, Liu J, Nie S, Li S, Yang J, Jiang Y, Cheng W. Construction of miRNA-mRNA Regulatory Network and Prognostic Signature in Endometrial Cancer. Onco Targets Ther 2021;14:2363-78. [PMID: 33854334 DOI: 10.2147/OTT.S272222] [Reference Citation Analysis]
611 Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009;58:1355-62. [PMID: 19266198 DOI: 10.1007/s00262-009-0686-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
612 Anestakis D, Petanidis S, Kalyvas S, Nday CM, Tsave O, Kioseoglou E, Salifoglou A. Mechanisms and applications of interleukins in cancer immunotherapy. Int J Mol Sci 2015;16:1691-710. [PMID: 25590298 DOI: 10.3390/ijms16011691] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
613 Holmes L Jr, Hossain J, Desvignes-Kendrick M, Opara F. Sex variability in pediatric leukemia survival: large cohort evidence. ISRN Oncol 2012;2012:439070. [PMID: 22550598 DOI: 10.5402/2012/439070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
614 Ács B, Madaras L, Tőkés A, Kovács AK, Kovács E, Ozsvári-vidákovich M, Karászi Á, Birtalan E, Dank M, Szász AM, Kulka J. PD-1, PD-L1 and CTLA-4 in pregnancy-related – and in early-onset breast cancer: A comparative study. The Breast 2017;35:69-77. [DOI: 10.1016/j.breast.2017.06.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
615 Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein RG, White MR, Zoller M, Iwakura Y, Dinarello CA, Voronov E, Apte RN. Host-Derived Interleukin-1α Is Important in Determining the Immunogenicity of 3-Methylcholantrene Tumor Cells. J Immunol 2009;182:4874-81. [DOI: 10.4049/jimmunol.0803916] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
616 Pileri A, Agostinelli C, Sessa M, Quaglino P, Santucci M, Tomasini C, Grandi V, Fava P, Astrua C, Righi S, Patrizi A, Pileri SA, Pimpinelli N. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch 2017;470:575-82. [DOI: 10.1007/s00428-017-2107-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
617 Imai N, Ikeda H, Tawara I, Wang L, Wang L, Nishikawa H, Kato T, Shiku H. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression. Cancer Sci. 2009;100:1317-1325. [PMID: 19432889 DOI: 10.1111/j.1349-7006.2009.01179.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
618 Lai SW, Huang BR, Liu YS, Lin HY, Chen CC, Tsai CF, Lu DY, Lin C. Differential Characterization of Temozolomide-Resistant Human Glioma Cells. Int J Mol Sci 2018;19:E127. [PMID: 29301329 DOI: 10.3390/ijms19010127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
619 Pastò A, Consonni FM, Sica A. Influence of Innate Immunity on Cancer Cell Stemness. Int J Mol Sci 2020;21:E3352. [PMID: 32397392 DOI: 10.3390/ijms21093352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
620 Cananzi FC, Quagliuolo V. Response to Letter to the Editor re: Cananzi, et al.: Surgery of leiomyosarcoma of the inferior vena cava. J Surg Oncol 2016;114:257. [PMID: 27189445 DOI: 10.1002/jso.24300] [Reference Citation Analysis]
621 Mühleisen B, Petrov I, Gächter T, Kurrer M, Schärer L, Dummer R, French LE, Hofbauer GFL. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 2009;55:67-76. [DOI: 10.1111/j.1365-2559.2009.03324.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
622 Cavassani KA, Carson WF 4th, Moreira AP, Wen H, Schaller MA, Ishii M, Lindell DM, Dou Y, Lukacs NW, Keshamouni VG, Hogaboam CM, Kunkel SL. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 2010;115:4403-11. [PMID: 20130237 DOI: 10.1182/blood-2009-09-241083] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 6.4] [Reference Citation Analysis]
623 Zhang X, Xiang J. Remodeling the Microenvironment before Occurrence and Metastasis of Cancer. Int J Biol Sci 2019;15:105-13. [PMID: 30662351 DOI: 10.7150/ijbs.28669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
624 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
625 Xu Y, Rogers CJ. Physical Activity and Breast Cancer Prevention: Possible Role of Immune Mediators. Front Nutr 2020;7:557997. [PMID: 33134306 DOI: 10.3389/fnut.2020.557997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
626 Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009;125:639-648. [PMID: 19425054 DOI: 10.1002/ijc.24355] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
627 Cui G, Shi Y, Cui J, Tang F, Florholmen J. Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets? Scand J Gastroenterol. 2012;47:367-377. [PMID: 22229663 DOI: 10.3109/00365521.2011.648950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
628 Wang F, Wang S, Zhou Q. The Resistance Mechanisms of Lung Cancer Immunotherapy. Front Oncol 2020;10:568059. [PMID: 33194652 DOI: 10.3389/fonc.2020.568059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
629 Ziemys A, Kim M, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Kwong L, Holder A, Boland G. Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Front Oncol 2020;10:757. [PMID: 32528881 DOI: 10.3389/fonc.2020.00757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
630 Sanchez CE, Dowlati EP, Geiger AE, Chaudhry K, Tovar MA, Bollard CM, Cruz CRY. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations. Transplant Cell Ther 2021;27:21-35. [PMID: 33007496 DOI: 10.1016/j.bbmt.2020.09.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
631 van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. J Immunol 2018;200:450-8. [PMID: 29311387 DOI: 10.4049/jimmunol.1701021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
632 Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12:86. [PMID: 23915189 DOI: 10.1186/1476-4598-12-86] [Cited by in Crossref: 1589] [Cited by in F6Publishing: 1573] [Article Influence: 176.6] [Reference Citation Analysis]
633 Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8:1811. [PMID: 29180759 DOI: 10.1038/s41467-017-01651-9] [Cited by in Crossref: 184] [Cited by in F6Publishing: 190] [Article Influence: 36.8] [Reference Citation Analysis]
634 Tosolini M, Algans C, Pont F, Ycart B, Fournié JJ. Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. Oncoimmunology 2016;5:e1188246. [PMID: 27622044 DOI: 10.1080/2162402X.2016.1188246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
635 Kirilovsky A, Sissy CE, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pagès C, Taieb J, Karoui M, Custers P, Dizdarevic E, Iseas S, Hansen TF, Jensen LH, Beets G, Gérard JP, Castillo-Martin M, Figueiredo N, Habr-Gama A, Perez R, Galon J, Pagès F. The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life? Oncotarget 2022;13:18-31. [PMID: 35018217 DOI: 10.18632/oncotarget.28100] [Reference Citation Analysis]
636 Hammerbacher J, Snyder A. Informatics for cancer immunotherapy. Ann Oncol 2017;28:xii56-73. [PMID: 29253114 DOI: 10.1093/annonc/mdx682] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
637 Le L, van Dams R, Lee P. Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients? Transl Lung Cancer Res 2019;8:S327-30. [PMID: 32038907 DOI: 10.21037/tlcr.2019.05.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
638 Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92. [PMID: 16177103 DOI: 10.4049/jimmunol.175.7.4583] [Cited by in Crossref: 216] [Cited by in F6Publishing: 197] [Article Influence: 12.7] [Reference Citation Analysis]
639 Sun S, Jiang C, Lin Y, Jin Y, Huang P. Enhanced T Cell Immunity by B7-H4 Downregulation in Nonsmall-Cell Lung Cancer Cell Lines. J Int Med Res 2012;40:497-506. [DOI: 10.1177/147323001204000211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
640 Panzarini E, Inguscio V, Dini L. Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int 2013;2013:482160. [PMID: 23509727 DOI: 10.1155/2013/482160] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
641 Bose S, Panda AK, Mukherjee S, Sa G. Curcumin and tumor immune-editing: resurrecting the immune system. Cell Div 2015;10:6. [PMID: 26464579 DOI: 10.1186/s13008-015-0012-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 8.7] [Reference Citation Analysis]
642 Ke M, Wang H, Zhang M, Tian Y, Wang Y, Li B, Yu J, Dou J, Xi T, Zhou C. The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. Biochem Pharmacol 2014;89:119-30. [PMID: 24630931 DOI: 10.1016/j.bcp.2014.02.024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
643 Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH, Ertl HC, Haydon PG, Weninger W. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 2006;203:2749-61. [PMID: 17116735 DOI: 10.1084/jem.20060710] [Cited by in Crossref: 172] [Cited by in F6Publishing: 163] [Article Influence: 10.8] [Reference Citation Analysis]
644 Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front Immunol 2020;11:784. [PMID: 32457745 DOI: 10.3389/fimmu.2020.00784] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
645 Wang ZK, Yang B, Liu H, Hu Y, Yang JL, Wu LL, Zhou ZH, Jiao SC. Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother 2012;61:911-6. [PMID: 22116346 DOI: 10.1007/s00262-011-1158-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
646 Murphy JF. Trends in cancer immunotherapy. Clin Med Insights Oncol 2010;4:67-80. [PMID: 20703326 DOI: 10.4137/cmo.s4795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
647 Rivadeneira DB, Delgoffe GM. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res 2018;24:2473-81. [PMID: 29386217 DOI: 10.1158/1078-0432.CCR-17-0894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
648 Li D, Cheng F. Threshold for extinction and survival in stochastic tumor immune system. Communications in Nonlinear Science and Numerical Simulation 2017;51:1-12. [DOI: 10.1016/j.cnsns.2017.03.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 3.4] [Reference Citation Analysis]
649 Collier SP, Henderson MA, Tossberg JT, Aune TM. Regulation of the Th1 genomic locus from Ifng through Tmevpg1 by T-bet. J Immunol 2014;193:3959-65. [PMID: 25225667 DOI: 10.4049/jimmunol.1401099] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 9.0] [Reference Citation Analysis]
650 Grange JM, Krone B, Stanford JL. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth. Eur J Cancer 2009;45:2266-73. [PMID: 19497734 DOI: 10.1016/j.ejca.2009.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
651 Pittet MJ, Grimm J, Berger CR, Tamura T, Wojtkiewicz G, Nahrendorf M, Romero P, Swirski FK, Weissleder R. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A 2007;104:12457-61. [PMID: 17640914 DOI: 10.1073/pnas.0704460104] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 5.0] [Reference Citation Analysis]
652 Dos Santos CMM, Diniz VLS, Bachi ALL, Dos Santos de Oliveira LC, Ghazal T, Passos MEP, de Oliveira HH, Murata G, Masi LN, Martins AR, Levada-Pires AC, Curi R, Hirabara SM, Sellitti DF, Pithon-Curi TC, Gorjão R. Moderate physical exercise improves lymphocyte function in melanoma-bearing mice on a high-fat diet. Nutr Metab (Lond) 2019;16:63. [PMID: 31528182 DOI: 10.1186/s12986-019-0394-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
653 Weadick CS, Duffy AG, Kelly RJ. Recent advances in immune-based approaches for the treatment of esophagogastric cancer. Expert Opin Emerg Drugs 2022;:1-13. [PMID: 34937483 DOI: 10.1080/14728214.2021.2020757] [Reference Citation Analysis]
654 Milano F, Krishnadath KK. Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens. Human Immunology 2008;69:614-24. [DOI: 10.1016/j.humimm.2008.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
655 Sun L, Lin Z, Duan X, Lu J, Ge Z, Li X, Li M, Xing E, Jia J, Lan T, Li W. Ganoderma lucidum polysaccharides antagonize the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells. Journal of Pharmacy and Pharmacology 2011;63:725-35. [DOI: 10.1111/j.2042-7158.2011.01266.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
656 Schijns V, Tartour E, Michalek J, Stathopoulos A, Dobrovolskienė NT, Strioga MM. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy 2014;16:427-39. [PMID: 24280238 DOI: 10.1016/j.jcyt.2013.09.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
657 Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Current Opinion in Oncology 2013;25:602-8. [DOI: 10.1097/cco.0000000000000020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
658 Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol 2008;45:1995-2006. [PMID: 18061676 DOI: 10.1016/j.molimm.2007.10.035] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 8.1] [Reference Citation Analysis]
659 Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A, Ono M, Matsumura Y, Kato M, Konishi K, Shiga T, Sano S, Sakaguchi S, Miyagawa-Hayashino A, Takahashi K, Uezato H, Miyachi Y, Tanioka M. CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer 2014;134:2393-402. [PMID: 24243586 DOI: 10.1002/ijc.28581] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
660 Andrews DM, Smyth MJ. Stress gets under your skin. Nat Immunol 2008;9:119-20. [PMID: 18204422 DOI: 10.1038/ni0208-119] [Reference Citation Analysis]
661 Shi C, Liu S, Tian X, Wang X, Gao P. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma. BMC Cancer 2021;21:1035. [PMID: 34530752 DOI: 10.1186/s12885-021-08765-w] [Reference Citation Analysis]
662 Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118:6-10. [PMID: 16003753 DOI: 10.1002/ijc.21303] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 8.5] [Reference Citation Analysis]
663 Dhouib I, Jallouli M, Annabi A, Marzouki S, Gharbi N, Elfazaa S, Lasram MM. From immunotoxicity to carcinogenicity: the effects of carbamate pesticides on the immune system. Environ Sci Pollut Res Int 2016;23:9448-58. [PMID: 26988364 DOI: 10.1007/s11356-016-6418-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
664 Cai W, Bao W, Chen S, Yang Y, Li Y. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma. Cancer Cell Int 2021;21:698. [PMID: 34930261 DOI: 10.1186/s12935-021-02378-w] [Reference Citation Analysis]
665 Adir Y, Tirman S, Abramovitch S, Botbol C, Lutaty A, Scheinmann T, Davidovits E, Arbel I, Davidovits G, Schneer S, Shteinberg M, Peretz Soroka H, Tirosh R, Patolsky F. Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles. Cancer Immunol Immunother 2018;67:1135-46. [PMID: 29785657 DOI: 10.1007/s00262-018-2173-5] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
666 Breart B, Lemaître F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 2008;118:1390-7. [PMID: 18357341 DOI: 10.1172/JCI34388] [Cited by in Crossref: 204] [Cited by in F6Publishing: 128] [Article Influence: 14.6] [Reference Citation Analysis]
667 Stelljes M, Specht C, Albring J, Volkmann S, Schl??sser V, Pauels H, Poremba C, Bisping G, Opitz C, Scheffold C, Silling G, Kiehl M, Berdel WE, Kienast J. Differential Requirement for a Cellular Type-1 Immune Response in Tumor-Associated Versus Alloantigen-Targeted GvT Effects: . Transplantation 2007;83:314-22. [DOI: 10.1097/01.tp.0000250725.95074.f1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
668 Sepe P, Mennitto A, Corti F, Procopio G. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. Immunotargets Ther 2020;9:273-88. [PMID: 33224904 DOI: 10.2147/ITT.S240889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
669 Saeed M, Xu Z, De Geest BG, Xu H, Yu H. Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. Bioconjug Chem 2020;31:404-15. [PMID: 31951380 DOI: 10.1021/acs.bioconjchem.9b00851] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
670 Pellicioli ACA, Bingle L, Farthing P, Lopes MA, Martins MD, Vargas PA. Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and T-cell analysis. J Oral Pathol Med 2017;46:928-33. [PMID: 28585308 DOI: 10.1111/jop.12597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
671 Zeng J, Harris TJ, Lim M, Drake CG, Tran PT. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int 2013;2013:658126. [PMID: 24324970 DOI: 10.1155/2013/658126] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
672 Scrimini S, Pons J, Sauleda J. Células mieloides supresoras: potencial vínculo entre la enfermedad pulmonar obstructiva crónica y el cáncer de pulmón. Archivos de Bronconeumología 2016;52:29-35. [DOI: 10.1016/j.arbres.2015.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
673 Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci 2017;24:15. [PMID: 28219375 DOI: 10.1186/s12929-016-0311-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
674 Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004;200:1581-92. [PMID: 15596524 DOI: 10.1084/jem.20041240] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 4.4] [Reference Citation Analysis]
675 Robert J, Cohen N. The genus Xenopus as a multispecies model for evolutionary and comparative immunobiology of the 21st century. Dev Comp Immunol 2011;35:916-23. [PMID: 21277325 DOI: 10.1016/j.dci.2011.01.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
676 Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA. 2005;102:9253-9257. [PMID: 15961541 DOI: 10.1073/pnas.0503852102] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.0] [Reference Citation Analysis]
677 Khanyile S, Masamba P, Oyinloye BE, Mbatha LS, Kappo AP. Current Biochemical Applications and Future Prospects of Chlorotoxin in Cancer Diagnostics and Therapeutics. Adv Pharm Bull 2019;9:510-20. [PMID: 31857956 DOI: 10.15171/apb.2019.061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
678 Sonnenschein C, Soto AM. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique. J Biosci 2013;38:651-63. [PMID: 23938395 DOI: 10.1007/s12038-013-9335-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
679 Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology 2015;4:e974411. [PMID: 26137405 DOI: 10.4161/2162402X.2014.974411] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 10.4] [Reference Citation Analysis]
680 Nair SS, Weil R, Dovey Z, Davis A, Tewari AK. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urol Clin North Am 2020;47:e17-54. [PMID: 33446323 DOI: 10.1016/j.ucl.2020.10.005] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
681 Shi Y, Li Z, Zheng W, Liu X, Sun C, Laugsand JB, Liu Z, Cui G. Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: Update. Immunobiology. 2015;220:1186-1196. [PMID: 26153874 DOI: 10.1016/j.imbio.2015.06.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
682 Carosella ED, Horuzsko A. HLA-G and cancer. Seminars in Cancer Biology 2007;17:411-2. [DOI: 10.1016/j.semcancer.2007.06.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
683 Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, Sato T, Yoshikawa H, Hara H, Shibuya A, Shibuya K. Increased Soluble CD155 in the Serum of Cancer Patients. PLoS One. 2016;11:e0152982. [PMID: 27049654 DOI: 10.1371/journal.pone.0152982] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
684 Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Front Immunol 2021;12:642285. [PMID: 34025653 DOI: 10.3389/fimmu.2021.642285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
685 Jang TJ, Kim SA, Kim MK. Increased number of arginase 1-positive cells in the stroma of carcinomas compared to precursor lesions and nonneoplastic tissues. Pathol Res Pract 2018;214:1179-84. [PMID: 29970307 DOI: 10.1016/j.prp.2018.06.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
686 Kvistborg P, Bechmann CM, Pedersen AW, Toh HC, Claesson MH, Zocca MB. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors. Vaccine 2009;28:542-7. [PMID: 19837091 DOI: 10.1016/j.vaccine.2009.09.129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
687 Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori 2017;103:405-21. [PMID: 28497847 DOI: 10.5301/tj.5000625] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
688 Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). Eur J Cancer 2020;137:30-9. [PMID: 32739767 DOI: 10.1016/j.ejca.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
689 Bhatia A, Kumar Y. Cancer stem cells and tumor immunoediting: putting two and two together. Expert Rev Clin Immunol 2016;12:605-7. [PMID: 26919116 DOI: 10.1586/1744666X.2016.1159133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
690 Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-727. [PMID: 16977338 DOI: 10.1038/nri1936] [Cited by in Crossref: 784] [Cited by in F6Publishing: 722] [Article Influence: 49.0] [Reference Citation Analysis]
691 Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, Aithal A, Bhatia R, Wannemuehler MJ, Narasimhan B, Solheim JC, Batra SK, Jain M. Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett 2018;417:35-46. [PMID: 29242097 DOI: 10.1016/j.canlet.2017.12.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
692 Kareva I, Luddy KA, O'Farrelly C, Gatenby RA, Brown JS. Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One? Front Immunol 2021;12:668221. [PMID: 34531851 DOI: 10.3389/fimmu.2021.668221] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
693 Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg 2011;115:505-11. [PMID: 21663411 DOI: 10.3171/2011.4.JNS101172] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
694 Marcucci F, Rumio C. The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer? Cell Mol Life Sci 2021;78:853-65. [PMID: 32940721 DOI: 10.1007/s00018-020-03606-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
695 Spel L, Boelens JJ, van der Steen DM, Blokland NJ, van Noesel MM, Molenaar JJ, Heemskerk MH, Boes M, Nierkens S. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget 2015;6:35770-81. [PMID: 26452036 D